

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 15/28, 17/02, 17/14 G01N 33/92, 33/537, 33/544 G01N 33/551	A1	(11) International Publication Number: WO 93/18067 (43) International Publication Date: 16 September 1993 (16.09.93)
(21) International Application Number: PCT/US93/02011 (22) International Filing Date: 4 March 1993 (04.03.93)		(74) Agents: GORMAN, Edward, H., Jr. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, One Abbott Park Road, Abbott Park, IL 60064-3500 (US).
(30) Priority data: 847,502 6 March 1992 (06.03.92) US 968,619 29 October 1992 (29.10.92) US		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, One Abbot Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: KUNDU, Samar ; 1313 Oxford Court, Libertyville, IL 60048 (US). LA FLEUR, Marie, Anne ; 2910 Owl Drive, Rolling Meadows, IL 60008 (US).		

(54) Title: IMMUNOCAPTURE ASSAY FOR DIRECT QUANTITATION OF SPECIFIC LIPOPROTEIN CHOLESTEROL LEVELS

(57) Abstract

The present invention relates to a method for directly measuring concentrations of cholesterol associated with specific lipoproteins in a plasma sample. The method involves the specific capture of intact lipoprotein particles containing cholesterol from a plasma sample with a specific lipoprotein binding agent. The quantity of the specific lipoprotein cholesterol present in the sample is then measured by detecting the amount of binding-agent-lipoprotein complexes that have formed in the reaction. The cholesterol contained in the binding-agent-lipoprotein complexes can be detected by reacting the complexes with labeled cholesterol specific binding agents and measuring the amount of label bound thereto, or by releasing the cholesterol in the complexes and measuring the amount of cholesterol released. The specific lipoprotein binding agent can be bound to a solid support. The assay method may also incorporate a further step of separating the solid support from the sample before detecting the presence of cholesterol bound to the solid support.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	L1	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Mongo	TG	Togo
DE	Germany	MC	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam

concentration by dividing the triglyceride concentration by 5
Although these assumptions may not be strictly true, the
equation generally provides LDL-cholesterol values within a
few mg/dL of those measured by the ultracentrifugation
5 method. However, large errors in the calculated LDL-
cholesterol concentration occur in the samples with
triglycerides exceeding 400 mg/dL. In such cases, the
Friedewald calculation-method is unacceptable. Several
studies have been conducted for the purpose of modifying
10 Friedewald's equation so that the calculated LDL-cholesterol
would better correlate with the ultracentrifugation method
(McNamara et al. (1990) *Clin. Chem.* 36:36-42; Warnick et al.
(1990) *Clin. Chem.* 36:15-19; Delong et al. (1986) *JAMA*
256:2372-2377), but no significant improvement has been
15 made. Like the ultracentrifugation method, the LDL-
cholesterol estimated by Friedewald's equation also contains
contributions from IDL cholesterol and Lp(a)-cholesterol.
Despite these limitations, both of the above methods are
commonly used. For example, in most of the epidemiological
20 studies wherein the relationship between LDL-cholesterol and
CHD was established (Bachorik (1989) *Clin. Lab. Med.* 9:61-72;
Castelli et al. (1986) *JAMA* 256:2823-2828) as well as in
studies of LDL-cholesterol lowering drugs (Stamler et al.
(1986) *JAMA* 256:2823-2828; Frick et al. (1987) *N. Engl. J.*
25 *Med.* 317:1237-1245; Blankenhorn et al. (1987) *JAMA*
257:3233-40; Lipid Research Clinics Program (1984) *JAMA*
251:351-374), one or both of these methods were used. Thus,
what is generally called "LDL-cholesterol" is actually a
measure of LDL-cholesterol, IDL cholesterol and Lp(a)-
30 cholesterol, each of which are thought to be atherogenic
markers. Moreover, Lp(a)-cholesterol concentration in plasma
is independent of total cholesterol, HDL-cholesterol or
triglycerides. Thus, the measurement of Lp(a) should be done
independently (Kurchinski et al. (1989) *Clin. Chem.* 35:2156-
35 2157). A method for estimating Lp(a)-cholesterol
concentration involves measuring the total Lp(a) mass in
plasma ([Lp(a)]) and calculating the Lp(a)-cholesterol

Because the unfractionated plasma layer ($[d > 1.006 \text{ g/mL chol}]$) also contains IDL and Lp(a) in addition to LDL and HDL, the LDL-cholesterol content of this fraction ($[LDL \text{ chol}]$) represents contributions from LDL, IDL, and Lp(a). In most cases, the contributions of remnants, IDL- and Lp(a)-cholesterol are only a few mg/dL and in all past epidemiological studies, their contributions were ignored. However, recent studies have indicated that IDL and Lp(a) are atherogenic markers. Elevated Lp(a) and IDL levels have been correlated with CHD and the progression of atherosclerotic lesions (Rhoads et al. (1986) *JAMA* 256:2540-2544; Guyton et al. (1985) *Arteriosclerosis* 5:265-272; Schriewer et al. (1984) *J. Clin. Chem. Clin. Biochem.* 22:391-396; Albers et al. (1974) *Lipids* 9:15-26; Albers et al. et al.(1974) *Biochem. Genetics* 11:475-486; Tatami et al. (1981) *Circulation* 64:1174-1784; Krauss et al. (1987) *Lancet* 2:62-66).

The ultracentrifugation method of LDL-cholesterol quantitation is time consuming, expensive, and requires specialized equipment, facilities and laboratory skills. A second method is more commonly used which simplifies this process. In this method the plasma LDL-cholesterol concentration is estimated by measuring three separate cholesterol concentrations: total-cholesterol ($[Total\text{-chol}]$), HDL-cholesterol ($[HDL\text{-chol}]$), and triglycerides concentration in the plasma. The LDL-cholesterol ($[LDL\text{-chol}]$) plasma concentration is then calculated using Friedewald's equation (Friedewald et al. (1972) *Clin. Chem.* 18:499-502) as follows:

$$[LDL\text{-chol}] = [Total\text{-chol}] - [HDL\text{-chol}] - [Triglycerides/5].$$

The factor $[Triglyceride/5]$ relates to the plasma VLDL-cholesterol concentration. It is assumed that all plasma triglycerides are associated with VLDL and that the ratio of triglyceride concentration to cholesterol concentration associated with VLDL is about 5. Thus, the VLDL-cholesterol concentration can be calculated from the triglyceride

- very low density lipoprotein (VLDL, $d < 1.006 \text{ g/mL}$), low density lipoprotein (LDL, $d 1.019-1.063 \text{ g/mL}$) and high density lipoprotein (HDL, $d 1.063-1.21 \text{ g/mL}$). Lesser amounts of cholesterol are also carried out in two minor lipoprotein classes, intermediate density lipoprotein (IDL, $d 1.006-1.019 \text{ g/mL}$) and lipoprotein (a) (Lp(a), $d 1.045-1.080 \text{ g/mL}$). LDL is the major contributor to the plasma total cholesterol concentration in man, accounting for the one-half to two-thirds of the plasma cholesterol.
- Two methods are presently available to determine the quantitative association between LDL-cholesterol and CHD. A first method, generally referred to as β -quantitation, is based on the use of combined ultracentrifugation and polyanion precipitation procedures (Havel et al. (1955) *J. Clin. Invest.* 34:1345-1353; McNamara et al. (1990) *Clin. Chem.* 36:36-42; Warnick et al. (1982) *Clin. Chem.* 28:1379-1388). In this method, an aliquot of plasma is used to measure the total cholesterol concentration in the sample. A second aliquot of plasma is centrifuged ($105,000 \times g$) at a plasma density of 1.006 g/mL for 18 hours at 4°C . After centrifugation, the upper layer containing VLDL and chylomicrons is removed. Chylomicrons ($d < 1.006 \text{ g/mL}$) are microscopic lipid particles that appear in the blood transiently after a fat-containing meal and are rich in triglycerides and usually have no significant effect on the total- and LDL-cholesterol concentration. An aliquot of the remaining bottom layer, which contains LDL, IDL, Lp(a) and HDL, is then used to measure the cholesterol concentration ($[d > 1.006 \text{ g/mL chol}]$) in this unfractionated plasma layer. LDL, VLDL, IDL and Lp(a) are precipitated from a second aliquot of the unfractionated plasma layer (Bachorik et al. (1986) *Methods in Enzymol.* 129 (B) 78-100) and the cholesterol concentration of HDL ($[HDL-chol]$) in the supernatant is measured. The cholesterol concentration of LDL ($[LDL chol]$) is then calculated using the following equation:
- $$[LDL chol] = [d > 1.006 \text{ g/mL chol}] - [HDL-chol].$$

IMMUNOCAPTURE ASSAY FOR DIRECT QUANTITATION
OF SPECIFIC LIPOPROTEIN CHOLESTEROL LEVELS

This application is a Continuation-In-Part of Application
5 Serial No. 07/847,502, filed March 6, 1992.

BACKGROUND OF THE INVENTION

Total plasma cholesterol is known to be an unreliable
10 marker for prediction of coronary heart disease (CHD) in many patients. Epidemiological studies have established several lipoprotein-related risk factors for coronary heart disease. Elevated plasma levels of cholesterol associated with low density lipoprotein (LDL) markedly increase the risk of CHD
15 (Castelli et al. (1986) JAMA 256:2835-2838). Lowering plasma LDL-cholesterol concentrations reduces the risk of CHD, myocardial infarction (MI) and CHD-related death (Lipid Res. Clinics Program (1984) JAMA 251:351-374; Frick et al. (1987) N. Engl. J. Med. 317:1237-1245; Blankenhorn et al.
20 (1987) JAMA 257:3233-3240; Stamler et al. (1986) JAMA 256:2823-2828). Moreover, reducing the plasma LDL-cholesterol concentration in patients also reduces the incidence of second heart attacks in MI survivors, slows down the progression of CHD and may also lead to regression of
25 coronary atherosclerosis (Brenski et al. (1984) 69:313-324). The National Cholesterol Education Program (NCEP) published recommendations for the detection and treatment of high blood cholesterol in adults for total- and LDL-cholesterol (Recommendations for improving cholesterol measurement
30 (1990) Bethesda:NIH Publication No. 90-2964). The recommended ranges for LDL-cholesterol are: <130 mg/dL (desirable); 130-159 mg/dL (borderline high); ≥160 mg/dL (high). No reliable method for the direct quantitation of LDL is yet available (Friedewald et al (1972) Clin. Chem. 18:499-
35 502; Warnick et al (1982) Clin. Chem. 28:1379-1388.

In the fasting state, plasma cholesterol is normally transported primarily in three major lipoprotein fractions,

concentration from the total Lp(a) mass concentration. The Lp(a)-cholesterol concentration is assumed to be about 30% of the total Lp(a) mass concentration (Kostner et al. (1981) *Atherosclerosis* 38:51-61). The calculated LDL-cholesterol concentration then can be corrected for Lp(a)-cholesterol using one of the following equations:

10 [LDL-chol] =
[Total-chol] - [HDL-chol] - [Triglyceride/5] - 0.3 [Lp(a)]
or
[LDL-chol] =
[d>1.006 g/ml chol] - [HDL-chol] - 0.3 [Lp(a)]

15 (Jurgens et al. (1987) *Neurology* 37:513-515; Sandkamp et al. (1990) *Clin. Chem.* 36:20-23). Alternatively, the Lp(a) concentration can be calculated from the plasma Lp(a)-protein concentration. The Lp(a)-protein concentration was measured by an ELISA test and the Lp(a) concentration was calculated by multiplying the Lp(a)-protein concentration by 4.21 (Fless et 20 al. (1989) *J. Lipid Res.* 30:651-662).

It is important that the Lp(a)-cholesterol correction be made in the LDL-cholesterol concentration because studies have shown that diet and drug treatment will reduce LDL-cholesterol levels but not Lp(a)-cholesterol levels and proper 25 patient monitoring requires an accurate measurement of LDL-cholesterol levels (Albers et al. (1975) *Metabolism* 24:1047-1054; Vessby et al. (1982) *Atherosclerosis* 44:61-71). This is particularly true for patients with elevated levels of Lp(a). For example, the Lp(a) concentration in some patients have 30 been found to be as high as 100 mg/dL (i.e., 30 mg/dL cholesterol) (Fless et al. U.S. Patent (1990) 4,945,040). In such patients, the LDL-cholesterol values will be erroneous if no correction is made for Lp(a)-cholesterol.

35 Direct methods for LDL-cholesterol measurement have been reported in the literature, but they involve selective precipitation of LDL from plasma. Three commercial kits (Boehringer Kit, Merck Kit, and Bio Merieux Kit) are available

and have been evaluated by Mulder, et al. ((1984) *Clin. Chim. Acta.* 143:29-35). The Boeringer Kit (Boeringer Mannheim, Federal Republic of Germany) uses selective precipitation of LDL with polyvinyl sulfate. The cholesterol content in the 5 supernatant is assayed and subtracted from the total serum cholesterol to obtain the LDL-cholesterol concentration. The Merck Kit (Merck, Darmstadt, Federal Republic of Germany) uses selective precipitation of LDL by heparin at pH 5.12. As in the Boeringer Kit, the LDL-cholesterol concentration is 10 calculated by subtraction of supernatant cholesterol from total cholesterol. The Bio Mérieux Kit (Bio Mérieux, Marcy-l'Etoile, France) uses selective precipitation of LDL with polycyclic surface active anions. After centrifugation and removal of the supernatant, the cholesterol content of the 15 precipitate is measured (Eur. Patent (1982) 0076211A2).

All three commercial methods agree well with isolated LDL fractions (d 1.019-1.063 g/ml) for samples with triglyceride concentrations below about 180 mg/dL but significantly overestimate the LDL-cholesterol concentration 20 for samples with higher triglyceride concentrations. However, the Mulder, et al. study cannot be compared directly with other studies because the isolated LDL fractions (d 1.019-1.063 g/mL) do not contain IDL (d 1.006-1.019 g/mL) and only contain a portion of Lp(a) that may have been present 25 ($Lp(a) \approx d$ 1.045-1.080 g/mL). No direct comparison of these kits was made with the ultracentrifugation-polyanion precipitation method. Also, the presence of lipoproteins other than LDL in the precipitate was not investigated.

Another method for direct LDL-cholesterol measurement 30 (Kerscher et al. (1988) U.S. Patent 4,746,605) involves the immunoprecipitation of HDL with HDL-specific antibodies and precipitation of VLDL with a mixture of polyanion and divalent cation. The location and effect of Lp(a) and IDL in the assay was not determined. Other precipitation or agglutination 35 methods useful in direct LDL measurement have been reported, such as cross-linked sulfated polyvinyl alcohol (Maaskant et al. (1986) U.S. Patent 4,623,628) as a binder for LDL, a water-

insoluble anion-exchanger which binds to VLDL and HDL (Maier et al. (1986) U.S. Patent 4,569,917), Ricinus Communis lectin as a agglutinating agent for LDL (Sears (1980) U.S. Patent 4,190,628), surfaces coated with anionic groups which have affinity for LDL (Knox et al. (1988) Eur. Patent 0319250A1), but none of these methods or reagents were evaluated with clinical samples.

- 5 Methods for the direct measurement of apolipoprotein B (apo B) utilizing apo B-specific antibody have been reported.
10 Such methods include competitive fluid phase and solid phase radio-immunoassays (RIA), an enzyme-linked immunosorbant assay (ELISA), a radial immunodiffusion assay (RIDA), an electroimmunoassay (EA), and an immunoprecipitation assay (IPA). However, the antisera used in these assays lacked
15 sufficient specificity to make the assays useful or reproducible. The methodological problems of each of these assays have been reviewed (Labey et al. (1990) *Clin. Chem.* 36:591-597; Curry et al. (1978) *Clin. Chem.* 24:280-286).

Other methods that have been used for directly
20 measuring LDL-cholesterol include separation and quantitation by high performance liquid chromatography (HPLC), gel filtration chromatography, analytical ultracentrifugation, sequential-density-gradient or zonal ultracentrifugation and electrophoresis. ("Methods in Enzymol." (1986) Vol. 128, Part
25 A; Vol. 129, part B). These methods generally require specialized skills and expensive equipment and are not readily adapted for use in routine analysis of patient samples.

An object of this invention is to develop a method of measuring LDL-cholesterol directly. Another object of this
30 invention is to eliminate the presence of IDL- and Lp(a)-cholesterol in the LDL-cholesterol measurement. Another object of this invention is to directly measure LDL-cholesterol easily, cheaply, quickly, and accurately without the need of highly trained technicians or expensive equipment such as an
35 ultracentrifuge. Still another object of this invention is to reduce the number of analytes and steps that are presently necessary to measure the LDL-cholesterol concentration. Yet

another object of this invention is to directly measure LDL-cholesterol without the analytical variability generally associated with LDL-cholesterol measurement.

While the role of Lp(a) in CHD has not been fully investigated, a significant correlation between elevated Lp(a) serum or plasma levels in humans, coronary artery disease and the progression of atherosclerotic lesions has been established (Seed et al. (1990) New England J. Med. 332:1494-1499). Lp(a) and LDL have common structural features. Both have a similar lipid composition and an apo B component. Lp(a), however, also contains two molecules of apolipoprotein (a) (apo(a)) covalently linked to the apo B molecule by at least one sulfide bond. Lp(a) concentrations in human plasma range from 1 mg/dL to more than 100 mg/dL. Lp(a) is known to be transmitted genetically by an autosomal dominant trait and 20 to 35% of normal individuals have Lp(a) plasma concentrations greater than 30 mg/dL. Lp(a) levels appear to be insensitive to changes in diet (Albers, et al. (1977) J. Lipid Res. 18:331-338) and treatment with cholestyramine (Vessby, et al. (1982) Atherosclerosis 44:61-71). Neomycin and niacin have been shown to reduce Lp(a) levels by 45% (Gurakar, et al. (1985) Atherosclerosis 57:293-301). However, the effect of diet and lipid-lowering drugs on the Lp(a)-cholesterol levels is not known. Another object of the present invention is to measure the plasma Lp(a)-cholesterol concentration of patients easily and accurately and thus allowing researchers to further investigate the relationship between Lp(a)-cholesterol concentrations and CHD.

A number of assay methods for quantitating Lp(a) in plasma are known (Morisett, et al. (1987) "Plasma Lipoproteins", A.M. Gotto, Jr., ed., Elsevier Science B.V., Chapter 5, pp. 129-152; Gaubatz, et al. (1986) "Methods in Enzymol." Vol. 129, pp. 167-187). The assays include radioimmunoassays, enzyme-linked immunosorbent assays, radial immunodiffusion, electroimmunoassays and immunoelectrophoresis. The assays commonly use antibodies directed against the apo(a) components of Lp(a) to measure

total Lp(a) or its protein content (Albers, et al. (1990) Clin. Chem. 36:2019-2026). These methods generally require trained technicians to perform these time-consuming methods and are not readily adaptable to routine analysis of patient samples. Moreover, none of these methods can quantitate the cholesterol content of Lp(a) directly from the patient sample. To quantitate the cholesterol concentration associated with Lp(a) in a patient sample, at a minimum the Lp(a) would have to be physically separated from the sample, such as by chromatographic or ultracentrifugal techniques, prior to measurement of the cholesterol concentration. Thus, another object of the present invention is to directly measure the Lp(a)-cholesterol concentration easily, cheaply, quickly, and accurately without the need of highly trained technicians or expensive equipment such as an ultracentrifuge.

SUMMARY OF THE INVENTION

The present invention relates to a method for directly measuring concentrations of cholesterol associated with specific lipoproteins in a plasma sample. The method involves the specific capture of intact lipoprotein particles containing cholesterol from a plasma sample with a specific lipoprotein binding agent. The quantity of the specific lipoprotein cholesterol present in the sample is then measured by detecting the amount of binding-agent-lipoprotein complexes that have formed in the reaction. The cholesterol contained in the binding-agent-lipoprotein complexes can be detected by a variety of standard methods known in the art such as, enzyme immunoassays, radioimmunoassays, ELISA, EMIT, and the like, or with labeled cholesterol specific binding agents. The specific lipoprotein binding agent can be bound to a solid support. The assay method may also incorporate a further step of separating the solid support from the sample before detecting the presence of cholesterol bound to the solid support. The present invention is also directed to a method

for selecting anti-LDL specific antibodies that are useful for detecting the amount of LDL-cholesterol in a sample.

BRIEF DESCRIPTION OF THE FIGURES

5

Figure 1: Typical antibody titer plots of the monoclonal antibody MB16 obtained by incubating microtiter plates with LDL, VLDL, IDL, HDL and Lp(a) bound to the plates in separate wells and measuring the antibody bound to the lipoproteins by 10 an ELISA assay.

Figure 2: Typical competitive binding curves of the monoclonal antibody MB16 obtained by pre-incubating the antibody with a lipoprotein, adding the mixture to a microtiter plate with LDL bound to the plate reaction wells and 15 measuring the antibody bound to the LDL by an ELISA assay.

Figure 3: Typical binding curves of the HRPO labeled MAB B06 with lipoproteins LDL, VLDL, IDL, HDL and Lp(a) as described in Example 3.

Figure 4: Typical binding curves of MABs 4B5.6, SPL4A5, 20 8A2.1, and 465C3D1 bound to microtiter plates for LDL-cholesterol using HRPO labeled MAB B06.

Figure 5: Typical binding curves of ^{125}I -LDL to MABs 2D8, 1D1 and MB16 immobilized on Immulon 2 Removawell strips.

25 Figure 6: Typical competitive displacement curves of ^{125}I -LDL for MAB 4B5.6 with lipoproteins LDL, VLDL, IDL, HDL and Lp(a).

Figure 7: A is a chart summarizing the composition of the two antigenic epitopes of apoB. B is a peptide map of the 30 apo B fragments formed by thrombin.

Figure 8: Typical peptide fragments of the apo B T2 fragment which are useful in generating LDL-specific MABs.

Figure 9: A typical cholesterol standard curve for a specific LDL-cholesterol assay of this invention.

35 Figure 10: A is a correlation curve for LDL-cholesterol measurements by the immunocapture assay using MAB SPL4A5-Sepharose and the ultracentrifuge method. B is a

correlation curve for LDL-cholesterol measurements by the immunocapture assay using MAB SPL4A5-Sepharose and the Friedewald method.

5 Figure 11: A is a correlation curve for LDL-cholesterol

measurements by the immunocapture assay using MAB 8A2.1-Sepharose and the ultracentrifuge method. B is a correlation curve for LDL-cholesterol measurements by the immunocapture assay using MAB 8A2.1-Sepharose and the Friedewald method.

10 Figure 12: A is a correlation curve for LDL-cholesterol

measurements by the immunocapture assay using MAB 4B5.6-Sepharose and the ultracentrifuge method. B is a correlation curve for LDL-cholesterol measurements by the immunocapture assay using MAB 4B5.6-Sepharose and the

15 Friedewald method.

Figure 13: A is a correlation curve for LDL-cholesterol

measurements by the immunocapture assay using MAB 4B5.6-Sepharose and the ultracentrifuge method corrected for Lp(a)-cholesterol. B is a correlation curve for LDL-cholesterol

20 measurements by the immunocapture assay using MAB 4B5.6-Sepharose and the Friedewald method corrected for Lp(a)-cholesterol.

Figure 14: A is a correlation curve for the ratio of LDL-

cholesterol concentrations determined by the immunocapture

25 assay using MAB 4B5.6-Sepharose and the ultracentrifugation method to the triglyceride concentration. B is a correlation curve for the ratio of LDL-cholesterol concentrations

determined by the immunocapture assay using MAB 4B5.6-Sepharose and the ultracentrifugation method corrected for

30 Lp(a)-cholesterol to the triglyceride concentration.

Figure 15: A is a correlation curve for the ratio of LDL-

cholesterol concentrations determined by the immunocapture

assay using MAB 4B5.6-Sepharose and the ultracentrifugation

method to the VLDL-cholesterol concentration. B is a

35 correlation curve for the ratio of LDL-cholesterol

concentrations determined by the immunocapture assay using MAB 4B5.6-Sepharose and the ultracentrifugation method

corrected for Lp(a)-cholesterol to the VLDL-cholesterol concentration.

Figure 16: A is a correlation curve for LDL-cholesterol measurements by the immunocapture assay using MAB MB16-Sepharose and the ultracentrifuge method. B is a correlation curve for LDL-cholesterol measurements by the immunocapture assay using MAB MB16-Sepharose and the Friedewald method.

Figure 17: A is a correlation curve for LDL-cholesterol measurements by the immunocapture assay using MAB MB16-Sepharose and the ultracentrifuge method corrected for Lp(a)-cholesterol. B is a correlation curve for LDL-cholesterol measurements by the immunocapture assay using MAB MB16-Sepharose and the Friedewald method corrected for Lp(a)-cholesterol.

Figure 18: A is a correlation curve for the ratio of LDL-cholesterol concentrations determined by the immunocapture assay using MAB MB16-Sepharose and the ultracentrifugation method to the triglyceride concentration. B is a correlation curve for the ratio of LDL-cholesterol concentrations determined by the immunocapture assay using MAB MB16-Sepharose and the ultracentrifugation method corrected for Lp(a)-cholesterol to the triglyceride concentration.

Figure 19: A is a correlation curve for the ratio of LDL-cholesterol concentrations determined by the immunocapture assay using MAB MB16-Sepharose and the ultracentrifugation method to the VLDL-cholesterol concentration. B is a correlation curve for the ratio of LDL-cholesterol concentrations determined by the immunocapture assay using MAB MB16-Sepharose and the ultracentrifugation method corrected for Lp(a)-cholesterol to the VLDL-cholesterol concentration.

Figure 20: A correlation curve for LDL-cholesterol measurements by the dry immunocapture assay using MAB 4B5.6 as described in Example 12 and the Friedewald method.

Figure 21: A correlation curve for LDL-cholesterol measurements by the indirect immunocapture assay using MAB

4B5.6-Sepharose as described in Example 13 and the Friedewald method.

Figure 22: Binding curves of the HRPO-digitonin conjugate of Example 16 to Lp(a)-cholesterol, LDL-cholesterol and VLDL-cholesterol particles.

5 Figure 23: A typical calibration curve plot of Lp(a)-cholesterol concentration versus absorbance prepared using the method of Example 18.

10

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method for determining the amount of cholesterol associated with a specific lipoprotein, such as LDL-cholesterol, in a sample. A

15 15 lipoprotein specific binding agent and a sample are mixed and incubated. The amount of cholesterol associated with the lipoprotein of interest present in the sample is then determined from the amount of cholesterol present in the binding-agent-lipoprotein complexes formed in the reaction.

20 20 The claimed method utilizes a lipoprotein specific binding agent to form a binding complex with lipoprotein particles in a sample. Following separation of the sample and the binding-agent-lipoprotein complexes, the amount of cholesterol associated with the lipoprotein in the complex is 25 25 then measured. Preferably, the lipoprotein particles are captured by a lipoprotein specific binding agent directly or indirectly bound to a solid support. This simplifies the separation of the resulting binding-agent-lipoprotein complexes.

30 30 Lipoprotein specific binding agents include lipoprotein specific binding proteins, such as monoclonal and polyclonal antibodies and other lipoprotein specific synthetic or recombinant proteins that specifically bind lipoprotein cholesterol particles. For example, an LDL specific binding 35 35 agent will include LDL specific binding proteins, such as monoclonal and polyclonal antibodies and other LDL specific synthetic and recombinant proteins, that specifically bind

LDL-cholesterol particles. Lipoprotein cholesterol particles are particles composed of a lipoprotein, such as LDL, VLDL, IDL, Lp(a), HDL and the like, containing cholesterol either directly or indirectly bound, coupled (ionically or covalently),
5 absorbed or adsorbed to the lipoprotein particles.

Preferably, the specific lipoprotein-cholesterol particles of interest are separated from other lipoprotein cholesterol particles in the sample before the cholesterol determination is made. For example, LDL-cholesterol
10 particles are selectively separated from HDL, Lp(a), IDL and VLDL-cholesterol particles prior to the measurement of the cholesterol associated with the LDL particles.

The lipoprotein specific binding agent can be attached directly or indirectly to a solid support, for example, by
15 absorption, adsorption, covalent coupling directly to the support or indirectly through another binding agent (such as an anti-antibody antibody), or the like. The type of attachment or binding will typically be dependent upon the material composition of the solid support and the type of lipoprotein
20 specific binding agent used in the assay. For example, nitrocellulose, polystyrene and similar materials possess chemical properties that permit absorption or adsorption of proteins to a solid phase composed of this material. Other materials, such as, latex, nylon and the like contain groups
25 that permit covalent coupling of the lipoprotein specific binding agent to the solid support. Groups, such as, amines and carboxylic acids are coupled through the activation of the carboxylic acid group with, for example, carbodiimide compounds, to form an amide linkage. Other linking methods
30 are well-known in the art particularly for coupling proteins to solid phases and one skilled-in-the-art can easily conceive of a variety of methods for covalently coupling the specific binding agent to the solid support. The solid support can take the form of a variety of materials, for example, the solid
35 support may be in the form of a bead particle, a magnetic particle, a strip or a layered device.

The separation of the binding-agent-lipoprotein complexes from the sample or more specifically from the other lipoprotein particles in the sample can be accomplished in a variety of ways. When the binding agent is coupled to a solid support, the solid support can be removed from the sample or the sample can be removed from the solid support. For example, when the solid support is a microtiter plate or another type of reaction well device, such as the devices described in US Patents 5,075,077 and 4,883,763 and US Patent Application Serial No. 523,629, incorporated herein by reference, the sample can be removed from the wells and the plate washed of any residual sample. When the solid support is a particle, such as a latex or magnetic particle, the solid support can be separated from the sample by filtration through a fiber matrix, such as the devices described in US Patents 4,552,839 and 5,006,309, US Patent Applications Serial Nos. 554,975, 611,235 and 425,651, and Fiore, et al (1988) Clin. Chem. 34/9:1726-1732, all of which are incorporated herein by reference, or by attraction to a magnet followed by removal of the particles or the sample. Alternatively, the binding-agent-lipoprotein complexes can be separated or removed by filtration such as by the Ion Capture Methodology described in co-pending US Patent Application Serial No. 150,278 and US Patent Application Serial No. 375,029, both of which enjoy common ownership and both of which are incorporated herein by reference. These applications describe the use of ion capture separation, in which specific binding members used in an assay are chemically attached to a first charged substance and a porous matrix having bound thereto a second charged substance that binds to the first charged substance. A specific binding pair is formed and separated from the reaction mixture by an electrostatic interaction between the first and second charged substances. The specific binding member is preferably covalently coupled to the first charged substance. Examples of charged substances include anionic and cationic monomers or polymers, such as polymeric acids, e.g.

polyglutamic acid, polyaspartic acid, polyacrylic acid and polyamino acids; proteins and derivative proteins, such as albumin; anionic saccharides, such as heparin or alginic acid; polycations, such as GafQuat™, diethylaminoethyl-dextran and cellulose derivatives such as polymeric quaternary ammonium compounds, such as Celquat™ L-200 and Celquat™ H-100. One skilled in the art is well versed in the separation of solid supports and samples.

The amount of cholesterol in or on a lipoprotein particle can be determined by a variety of methods. For example, lipoprotein cholesterol (such as LDL-cholesterol) can be detected chemically by using the Liebermann-Burchard method or modifications of their method; enzymatically using a cholesterol specific enzyme such as cholesterol oxidase; through the formation of a cholesterol specific binding complex, such as an anti-cholesterol antibody/cholesterol complex; or through the release of the cholesterol from the lipoprotein followed by detecting the amount of cholesterol released using any of the above methods. One skilled-in-the-art may conceive of yet other methods of detection applicable to this method.

For purposes of illustration, an LDL-cholesterol measurement can be made as follows. LDL particles present in a plasma sample are specifically captured by an LDL-specific monoclonal antibody immobilized on a solid support. After separating the solid support from the other unbound plasma lipoproteins, the cholesterol content of the bound LDL particles is estimated by releasing the cholesterol and its esters with a detergent solution. A Standard Cholesterol assay reagent comprising of cholesterol ester hydrolase, cholesterol oxidase and horseradish peroxidase is added. The liberated hydrogen peroxide is then quantitated using a Tinder dye reagent comprising of 4-aminoantipyrine and 3,5-dichloro-2-hydroxybenzenesulfonic acid similar to that described (Sidel et al (1983) *Clin. Chem.* 29:1075-1079). The cholesterol concentration in a given sample is quantitated on the basis of the color generation.

- Alternatively, a sandwich immunoassay method for the quantitation of LDL-cholesterol in a plasma sample can be used. This involves the specific capture of the LDL particles in the plasma sample by the LDL-specific antibody
- 5 immobilized on the solid support followed by quantitation of cholesterol in the captured LDL particles by a cholesterol binding agent which is coupled directly or indirectly to a label. The LDL-cholesterol bound cholesterol binding agent is then quantitated by detection and measurement of the label.
- 10 Another alternative is based on an immunochromatographic assay format (such as described in US Patent 4,954,452 and co-owned and copending U.S. Patent Application Serial No. 072,459, incorporated herein by reference), in which the lipoprotein particles in the test
- 15 sample bind to a labeled cholesterol binding agent. The resulting complexes then travel along a test strip by capillary action. The labeled LDL complexes are then captured by a high affinity anti-LDL specific antibody immobilized on the test strip followed by detection and measurement of the captured
- 20 labeled LDL complexes. Typically, the test strip is comprised of a porous or bibulous membrane and the result is determined by a visual readout of a detectable signal.
- The term "label", as used herein, refers to any substance which can be attached to specific binding agents, such as
- 25 antibodies, antigens, cholesterol binding agents, lipoprotein specific binding agents and analogs thereof, and which is capable of producing a signal that is detectable by visual or instrumental means. Various suitable labels for use in the present invention can include chromogens, catalysts,
- 30 fluorescent compounds, chemiluminescent compounds, radioactive elements, colloidal metallic (such as gold), non-metallic (such as selenium) and dye particles (such as the particles disclosed in U.S. Pat. Nos. 4,313,734, 4,954,452 and 4,373,932, incorporated herein by reference), enzymes, enzyme
- 35 substrates, and organic polymer latex particles (as disclosed in co-owned and copending U.S. Patent Application Serial No. 248,858, filed September 23, 1988, which is incorporated by

reference herein), liposomes or other vesicles containing such signal producing substances, and the like. A large number of enzymes suitable for use as labels are disclosed in U.S. Patent No. 4,275,149, incorporated herein by reference. Such enzymes 5 include phosphatases and peroxidases, such as alkaline phosphatase and horseradish peroxidase which are used in conjunction with enzyme substrates, such as nitro blue tetrazolium, -3,5',5,5'-tetranitrobenzidine, -4-methoxy-1-naphthol, 4-chloro-1-naphthol, 5-bromo-4-chloro-3-indolyl 10 phosphate, chemiluminescent enzyme substrates such as the dioxetanes described in US Patents 4,857,652 (issued August 15, 1989), 4,931,223 (issued June 5, 1990), 4,931,569 (issued June 5, 1990), 4,962,192 (issued October 9, 1990) and 4,978,614 (issued December 18, 1990), incorporated herein by 15 reference, and derivatives and analogs thereof. Fluorescent compounds such as fluorescein, phycobiliprotein, rhodamine and the like, including their derivatives and analogs are suitable for use as labels.

Cholesterol binding agents bind specifically to 20 cholesterol and include digitonin, tomatine, filipin, amphotericin B and specific binding proteins such as polyclonal and monoclonal antibodies and other synthetic and recombinant proteins that specifically bind cholesterol, cholesterol esters and/or the cholesterol associated with 25 lipoprotein particles. A number of cholesterol binding agents are known in the literature. These include saponins such as digitonin (Berezin et al. (1980) Vopr. Med. Khim. 26:843-846; Tsybul's kaya et al. (1986) Bioorg. Khim. 12:1391-1395), tomatine (Schultz and Sanders (1957) Z. Physiol. Chem. 30 308:122-126; Eskelson et al. (1967) Clin. Chem. 13:468-474), filipin (Boernig et al. (1974) Acta Histochem. 50:110-115; Behnke et al. (1984) Eur. J. Cell Biol. 35:200-205), amphotericin B (Braitburg et al. (1984) J. Infect. Dis. 149:986-997), triterpene glycoside halotoxin A1 and related compounds 35 (Ivanov et al. (1986) Vopr. Med. Khim. 32:132-134). Both monoclonal and polyclonal antibodies to cholesterol are also

known (J. Immunol. (1964) 92:515; Nature (1965) 407; Proc. Natl. Acad. Sci. USA (1988) 85:1902).

Digitonin, tomatine, amphotericin B and antibodies can be used in the quantitation of cholesterol and its esters in lipoprotein particles. Digitonin and tomatine were chemically modified and then conjugated to horseradish peroxidase (HRPO) and alkaline phosphatase (AP). Amphotericin B and anti-cholesterol antibodies were coupled directly to HRPO and AP. All four HRPO and AP conjugates bind to cholesterol and its esters in lipoproteins which are immobilized on a solid phase. The binding affinity of the enzyme conjugates follow the order digitonin > tomatine > anti-cholesterol antibodies > amphotericin B. Because digitonin conjugates and tomatine conjugates bound effectively to the cholesterol components of lipoproteins, these conjugates are preferred in the present invention.

A method of the present invention is illustrated by the following sandwich assay example. The method involves incubating the sample with a solid phase having an LDL specific binding agent, such as the monoclonal antibody 4B5.6, immobilized on a solid phase and the remaining non-specific binding sites of the solid phase blocked, such as with bovine serum albumin or alkali-treated casein. LDL particles are captured by the antibody on the solid phase. Digitonin or tomatine enzyme conjugates are then incubated with the solid phase. The conjugate binds to the cholesterol associated with the LDL particles on the solid phase. The quantity or presence of enzyme bound to the solid phase or the quantity of unbound conjugate remaining after incubation with the solid phase is determined by incubation of enzyme substrate with the solid phase or the solution containing unbound conjugate. The presence of cholesterol associated with the captured LDL particles is then determined from the presence of enzyme associated with the solid phase or a reduction of enzyme activity in the solution containing unbound conjugate as compared with the original conjugate solution added to the solid phase. The quantity of cholesterol associated with the

captured LDL particles is proportional to the quantity of enzyme associated with the solid phase or inversely proportional to the quantity of unbound conjugate. This method is also applicable for any of the other lipoprotein particles or mixtures thereof by substituting the appropriate lipoprotein specific binding agent for the LDL specific binding agent.

A critical aspect of this invention is the selection of the lipoprotein specific binding agents. A lipoprotein specific binding agent preferably must selectively bind to the lipoprotein of interest, but not to other lipoproteins. For example, an LDL specific binding agent preferably binds only to LDL and not to other lipoproteins, such as HDL, VLDL, IDL and Lp(a). In addition, when the cholesterol binding agent is 10 an antibody, the lipoprotein specific binding agent and the cholesterol binding antibody must be compatible such that neither binding agent interferes with the binding of the other agent to the lipoprotein particle and cholesterol associated 15 with the particle. The preferred lipoprotein specific binding agent is an antibody which binds specifically to the lipoprotein of interest. The antibody is preferably a monoclonal antibody. Monoclonal antibodies are preferable because production quantities of antibody are readily available and such antibodies generally improve the lot-to-lot 20 reproducibility and consistency in the assay results.

The term antibody is also meant to include both intact molecules as well as fragments thereof, such as, for example, Fab and F(ab')₂, which are capable of binding antigen. Fab and F(ab')₂ fragments lack the Fc fragment of intact antibody and 25 may have less non-specific binding than an intact antibody (Wahl, et al., J. Nucl. Med. 24:316-325, 1983). Such fragments also may be used for the detection and quantitation of lipoprotein cholesterol particles according to the methods disclosed herein in the same manner as intact antibodies. 30 Such fragments are well known in the art and are typically produced by enzymatic degradation of an antibody, such as with pepsin, papain or trypsin. Alternatively, antibodies and 35

- antibody fragments can be prepared using recombinant antibody methods such as those described in US Patent Applications Serial Nos. 513957, 693249, 789619, 776391, 799770, 799772, and 809083, incorporated herein by reference, wherein antibodies or antibody fragments are produced from the RNA of an antibody producing B-cell from an immunized animal, such as a rat or mouse, using known recombinant techniques.

Lipoprotein specific binding agents according to the present invention also include bacteriophage described in US Patent 4,797,363, incorporated herein by reference. Bacteriophage tail or head segments are capable of selectively binding antigens. By mutation and selection processes, bacteriophage having the necessary binding characteristics to selectively bind lipoprotein cholesterol particles can be obtained.

Lipoprotein specific binding agents according to the present invention also include nucleic acid sequences, such as DNA and RNA, which selectively bind to lipoprotein cholesterol particles. A library of nucleic acid sequences are tested for the desired binding characteristics and the sequences that are specific for lipoprotein cholesterol particles are isolated and replicated. Weintraub, et al., WO 92/05285, and Gold, et al., WO 91/19813, both incorporated herein by reference, disclose methods for the preparation of DNA and RNA sequences which are antigen specific.

Preferably, the lipoprotein specific binding agent is selective for only one lipoprotein, but some recognition of or binding to other lipoproteins can be tolerated. For example, an antibody selected for its ability to bind only to LDL particles present in a sample can minimally capture other lipoproteins and still be utilized in this invention. More specifically, the present invention can tolerate an LDL specific monoclonal antibody that does not cross-react with Lp(a) or HDL, but does cross-react with VLDL up to 20% and with IDL up to 20%. In addition, the LDL specific monoclonal antibody should not

cross-react with other lipoprotein and non-lipoprotein materials present in a sample.

- The measurement of a specific lipoprotein cholesterol level can also be accomplished indirectly by removing all the other lipoproteins from the sample. The selective binding agents of a group of selected lipoproteins can be used to remove these lipoproteins from a sample, leaving behind substantially only one lipoprotein in the sample. Measurement of the cholesterol in the sample after this group of lipoproteins have been removed gives an indication of the amount of cholesterol present in the remaining lipoprotein. For example, selectively removing HDL, VLDL, IDL and Lp(a) will essentially leave behind LDL in the sample. Measurement of the cholesterol in the remainder of the sample gives an indication of the LDL-cholesterol present in the sample. The cholesterol levels associated with the other lipoproteins could be measured by simply changing the group of selected lipoproteins removed from the sample. Moreover, lipoprotein specific binding agents, such as antibodies, that are not selective for only one lipoprotein, such as an antibody that binds to both VLDL and LDL but not Lp(a), can be used to remove the antibody cross-reacting lipoproteins (VLDL and LDL) in the measurement of cholesterol associated with a non-cross reacting lipoprotein (Lp(a)) using this indirect method.
- This indirect approach can also improve the efficacy of lipoprotein specific binding agents, used in the direct measurement of a specific lipoprotein, that are not sufficiently selective for the lipoprotein of interest. By removing an antibody cross-reacting specific lipoprotein from the sample prior to specifically measuring the lipoprotein cholesterol of interest, the effect of such cross-reactivity is eliminated.
- Moreover, the sequential removal and measurement of specific lipoprotein cholesterol levels from the same aliquot of sample permits the use of less selective lipoprotein selective binding agents in the measurement of lipoprotein cholesterol levels later in the sequence. For example, an antibody that binds to both VLDL and LDL could be used to

selectively capture VLDL if the LDL present in the sample had previously been removed.

The present invention has the capability of quantitating the amount of cholesterol associated with lipoproteins. This advancement in technology will more clearly define the correlation between lipoprotein cholesterol levels and CHD. For example, by specifically detecting LDL-cholesterol and not the cholesterol associated with other lipoproteins present in a plasma sample, the present invention improves the precision, accuracy and reproducibility of LDL-cholesterol measurement of a sample and thereby a better indication of the association of the LDL-cholesterol level with CHD. Thus, the dietary or therapeutic drug treatment of a patient can now be more carefully monitored for improved results in lowering the risk of CHD in the patient. Moreover, the simplicity of performing LDL-cholesterol measurements will also be improved. Determination of LDL-cholesterol levels by multiple measurements of various lipoprotein cholesterol levels will no longer be necessary.

20 The following examples are illustrative of the invention and are in no way to be interpreted as limiting the scope of the invention as defined in the claims. It will be appreciated that one skilled-in-the-art can conceive of many other devices and methods for use of which the present inventive concepts can be applied.

25

LDL-CHOLESTEROL SPECIFIC ASSAY

1. SOURCES OF THE MONOCLONAL ANTIBODIES

30 Monoclonal antibodies (MABs) were procured from five different laboratories. SPL4A5, 8A2.1, 8B3.5, and 8A6.6 (IgG1), and 4B5.6 (IgG2b) were obtained from Alexander Karu, University of California at Berkeley as ascites precipitated by 35 50% ammonium sulfate and dialyzed against TRIS buffer pH 7.2. The MAB SPL4A5 is described in U.S. Patent 4,619,895 for use in the diagnosis of patients suffering from Type IV

- hypertriglyceridemia. The blood of such patients contains LDL particles of size between 215-230 Å which is not present in normal individuals. The antigenic epitope of these LDL particles which is recognized by the MAB SPL4A5 was not disclosed. The MABs 8A2.1, 8B3.5, 8A6.6 and 4B5.6 were described in LaBelle, et al. (1990) *Clin. Chimica Acta.* 191:153-160. These four MABs reportedly reacted with LDL and apo B, but not with HDL. The antigenic epitopes of the LDL and apo B which were recognized by the four MABs were determined by Western blot using apo B fragments cleaved from apo B by thrombin. The MABs 8A2.1, 8A6.6 and 8B3.5 recognized thrombolytic fragment T3 and the MAB 4B5.6 recognized only thrombolytic fragment T2. Prior to use in the experiments herein, the MABs were purified on a Protein A Sepharose column as described in Example 1 (*infra*). The MABs SPL4A5, 8A2.1, 8A6.6 and 8B3.5 were eluted from the column with pH 6.0 citrate buffer and the MAB 4B5.6 was eluted from the column with pH 4.0 citrate buffer.
- MABs BI9, B18, B06, B05, B04 and B02 were obtained from Jean-Charles Fruchart, SERLIA Institut Pasteur, Lille Celdex, France, as purified IgG fractions.
- MABs 457C4DI, 465C3DI, 464BIB3, and 464BIB6 were obtained from Gustav Schonfeld, Washington University Medical Center, St. Louis, MO. These MABs are all IgG1 and were described in Tikkanen, et al. (1982) *J. Lipid Res.* 23:1032-1038; and Tikkanen, et al. (1983) *J. Lipid Res.* 24:1494-1499. The MABs differed in reactivity toward LDL obtained from different individuals and were suggested to recognize different antigenic epitopes of LDL. The MABs were supplied in ascites fluid and were purified on Protein A Sepharose column as described in Example 1 (*infra*). All four antibodies were eluted from the column with citrate buffer at pH 6.0.
- MABs apo B_{sol}16 (MB16), 2D8 and IDI (IgG1), and 5EII (IgG2a) were obtained from Yves Marcel, Clinical Research Institute of Montreal, Canada. The MABs were characterized and the antigenic epitopes of apo B recognized by these MABs was determined using apo B fragments cleaved from apo B by

thrombin, synthetic oligopeptides and recombinant proteins (Marcel, et al. (1987) Mol. Immunol. 24:435-447; Marcel, et al. Arteriosclerosis (1987) 7:166-175; Chen, et al. (1988) Eur. Biochem. 175:111-118; and Knott, et al. (1986) Nature 5 323:734-738). MAB MB16 recognized the peptide residues 4154-4189 of thrombolytic fragment T2. MAB IDI recognized the peptide residues 1-1297 of thrombolytic fragment T4. MAB 2D8 recognized the peptide residues 1297-2177 of thrombolytic fragment T3. MAB 5EII recognized the peptide 10 residues 2488-3636 in the T3/T2 region of LDL (B,E) receptors. All four MABs were reported to react with LDL and solubilized apo B. Regarding their reactivity with VLDL, MABs IDI, 2D8 and 5EII required the presence of lipids in order to react with VLDL, whereas MAB MB16's reactivity was found to 15 be lipid independent. The MABs were obtained as 50% ammonium sulfate precipitates of the ascites fluid. Prior to use herein, the MABs were purified on Protein A Sepharose columns as described in Example 1 (*infra*). MAB 5EII was eluted from the column with pH 5 citrate buffer and the others 20 were eluted from the column with pH 6 citrate buffer.

Three purified anti-LDL monoclonal antibodies A016-08, A016-09, and A016-10 were obtained from Medix Biotech, Foster City, CA. All three purified anti-LDL MABs were characterized in terms of their cross-reactivities with other 25 lipoproteins in order to select LDL-specific antibodies. The selected antibodies bound to LDL particles of blood samples from normal individuals and from individuals with high triglycerides blood levels (300-400 mg/dL), did not bind to Lp(a) or HDL, and reacted with VLDL and IDL at less than about 30 10% of the LDL reactivity. Suitable antibodies for use in the present invention bind to (1) Lp(a) preferably at less than about 5% of the LDL reactivity and more preferably at less than about 2% of the LDL reactivity; (2) HDL preferably at less than about 2% of the LDL reactivity and more preferably at 35 less than about 1% of the LDL reactivity; and (3) VLDL and IDL, preferably at less than about 20% of the LDL reactivity and more preferably at less than about 10% of the LDL reactivity.

2. EVALUATION OF THE MONOCLONAL ANTIBODIES

The following methods were used to evaluate the
5 antibodies.

a. Direct ELISA using lipoprotein coated microtiter plates

Lipoprotein fractions (LDL, HDL, VLDL, IDL and Lp(a))
10 purified by ultracentrifugation (see Example 2, *infra*) were
coated on separate wells of a Maxisorb Nunc Immuno Plate as
follows: one hundred microliters (100 µL) of each lipoprotein
fraction at a lipoprotein-cholesterol concentration of about 1
µg/ml in 20 mM phosphate buffered saline at pH 7.0 (PBS) was
15 dispensed into separated wells of the microtiter plate, the
plate was incubated at 37°C for one hour, and the plate was
then washed five times with PBS containing 0.05% (v/v)
Tween 20 (PBS-Tween 20). The non-specific binding sites
were blocked with 200 µL of 10% (v/v) fetal bovine serum
20 (FBS) in PBS at 37°C for one hour and then were washed five
times with PBS-Tween 20. Each MAB was diluted in 3% (v/v)
FBS in PBS to a final antibody concentration of about 2 µg/ml
and the diluted MAB solutions were then serially diluted on
the plates. After incubation at 37°C for one-half hour, the
25 plate was washed five times with PBS-Tween 20. Thereafter,
one hundred microliters (100 µL) of horseradish peroxidase
(HRPO) labeled goat anti-mouse IgG (obtained from Kirkegaard
and Perry Laboratories, MD), diluted in 3% FBS in PBS to a
final concentration of about 1.25 µg/mL, were added to each
30 reaction well and the plate was incubated at 37°C for one-half
hour. The plate was then washed eight times with PBS-Tween
20. One hundred microliters (100 µL) of freshly prepared
HRPO substrate solution, containing one o-phenylenediamine
(OPD) tablet per five milliliters (5 mL) of citrate buffer at pH
35 6 (both available from Abbott Laboratories, IL), were added to
each well. The color reaction was stopped after five minutes
by adding 100 µL of 1N H₂SO₄ to the reaction wells. An

absorbance reading of each reaction well was then obtained with a Bio-Tek microplate reader at 490 nm. Typical binding curves for each lipoprotein tested with MAB MB16 are shown in Figure 1. A summary of test results are presented in Table 5 1 which shows the binding efficiencies of the lipoproteins relative to LDL at an antibody concentration of about 1 µg/mL. MABs 4B5.6 and A016-08 did not show any binding with LDL even at an antibody concentration of about 2 µg/mL. MABs SPL4A5, 8A2.1 and 465C3D1 produced absorbance readings of

10

TABLE 1
BINDING OF MABs TO LIPOPROTEINS ON SOLID PHASE

MAB*	LDL	VLDL	IDL	Lp(a)	HDL
B19	100	40	46	2	0
B18	100	20	62	3	0
B06	100	18	59	2	0
B05	100	57	80	1	0
B04	100	34	72	0	0
B02	100	9	77	0	0
4B5.6	0	0	0	0	0
SPL4A5	100	42	84	0	0
8A2.1	100	32	90	0	0
8B3.5	100	26	9	0	0
8A6.6	100	15	69	0	0
465C3D1	100	0	0	0	0
457C4D1	100	28	19	0	0
464B1B3	100	42	32	0	0
464B1B6	100	41	26	0	0
MB16	100	23	43	16	7
2D8	100	38	60	12	5
1D1	100	22	36	13	0
5E11	100	34	51	18	4
A016-08	100	0	0	0	0
A016-09	100	47	67	20	0
A016-10	100	54	78	27	4

* At 1 µg/mL antibody concentration.

about 0.2 at 490 nm. The low binding (affinity) of these MABs may possibly be due to unfavorable orientation of the lipoproteins on the solid phase which could interfere with the accessibility of the antigenic epitopes by the antibodies 5 resulting in little or no binding by the antibodies. These MABs would thus be lipoprotein conformation-dependent.

b. Specificity of the antibodies for LDL using lipoprotein-coated microtiter plates in competitive assays

- 10 The specificities of the MABs were determined by competitive binding of the MABs to the other lipoproteins in microplate wells coated with LDL. The LDL-coated plates were prepared as described previously (see section 2a above).
- 15 Each MAB was diluted with 3% (v/v) FBS in PBS to a concentration that was two times the MAB concentration at 50% LDL-binding as determined from the binding curves prepared in section 2a above. Examples of such curves are shown in Figure 1. Purified lipoprotein samples were diluted
- 20 in PBS starting at the following cholesterol concentrations: LDL-cholesterol concentration of 45 mg/dL; VLDL-cholesterol concentration of 45 mg/dL; IDL-cholesterol concentration of 22.5 mg/dL; HDL-cholesterol concentration of 22.5 mg/dL; and Lp(a) at a total mass of Lp(a) of 22.5 mg/dL. Fifty microliters
- 25 (50 µL) of each lipoprotein solution were then serially diluted with PBS in reaction wells blocked by 10% (v/v) FBS in PBS. To each of these wells were added 50 µL of the diluted MAB solutions. The MAB-lipoprotein mixtures were incubated at room temperature for one-half hour on a rotator at 100 rpm.
- 30 The contents from each well were then transferred to LDL-coated reaction wells and the plates were incubated at 37°C for one-half hour. The amount of MAB bound to the LDL-coated reaction wells were measured according to the method described in section 2a above. Typical competitive binding
- 35 curves are shown in Figure 2. A summary of the test results are presented in Table 2. The cross-reactivities were

determined at 50% inhibition of binding by a competing lipoprotein using the following equation:

$$5 \quad \text{cross-reactivity (\%)} = \frac{\text{amount needed by LDL}}{\text{amount needed by competitor}} \times 100$$

MAB B18 did not show any inhibition of binding even by LDL. The results also indicate extensive binding of all MABs, particularly with IDL. This is in contrast to the binding curves obtained in section 2a above. For example, MB16 in Figure 1 shows much less affinity towards VLDL and IDL, whereas MB16 in Figure 2 shows almost equal affinity for both LDL and IDL. This indicates that the affinity of the MABs toward lipoproteins differs depending on whether the reaction

TABLE 2
COMPETITIVE BINDING OF MABs BY ELISA

MAB	% Cross-Reactivity with LDL			
	VLDL	IDL	Lp(a)	HDL
B19	42	53	1	0
B18	NO INHIBITION WITH LDL OR OTHER LIPOPROTEINS			
B06	37	52	7	0
B05	34	82	5	0
B04	39	59	6	0
8B3.5	35	100	0	0
8A6.6	50	100	0	0
457C4D1	50	100	0	0
464B1B3	47	94	5	0
464B1B6	29	81	15	0
MB16	100	105	21	10
2D8	56	105	50	48
1D1	140	100	37	30
5E11	41	41	21	21
A016-09	95	100	22	22
A016-10	100	55	29	25

is done with a solid phase (Figure 1) or in a fluid phase (Figure 2). Therefore, any published conclusions relating to the reactivities of these MABs using only one of these methods is suspect and unreliable. Thus, we developed an assay where
5 lipoprotein specific antibodies are immobilized on the solid phase in order to capture specific lipoproteins to avoid the inconsistencies observed in the above methods.

c. Direct ELISA using antibody coated microtiter plates
10

MABs were coated onto the reaction wells of microtiter plates as follows. MABs were diluted in PBS as follows:
SPL4A5 (20 µg/mL), 8A2.1 (20 µg/mL), 8A6.6 (2 µg/mL),
4B5.6 (3 µg/mL), 8B3.5 (5 µg/mL), 465C3D1 (2 µg/mL),
15 457C4DI (2 µg/mL), 464B1B3 (1.5 µg/ml), 464BIB6 (1.5 µg/mL), B19 (2 µg/mL), B18 (2.5 µg/mL), B06 (10 µg/mL),
B04 (10 µg/mL), B02 (4 µg/mL), MB16 (5 µg/mL), IDI (5 µg/mL), 2D8 (5 µg/mL), 5EII (5 µg/mL), A016-08 (10 µg/mL),
A016-09 (10 µg/mL) and A016-10 (10 µg/mL). One hundred
20 microliters (100 µL) of each MAB solution were dispensed into separate reaction wells and incubated at room temperature on a rotator at 100 rpm for two hours. The plates were then washed five times with PBS-Tween 20 and blocked with 200 µL of 10% FBS in PBS by incubation at 37°C for one hour. The
25 plates were then washed five times with PBS-Tween 20.

Each MAB plate was then serially diluted with LDL in PBS, starting with an LDL-cholesterol concentration of 10 mg/dL cholesterol, so that each well contained a total of 100 µL of solution. After incubation at 37°C for one-half hour, the
30 plates were washed five times with PBS-Tween 20. One hundred microliters (100 µL) of 0.6 µg/ml MAB B06-HRPO conjugate (prepared according to Example 3 and Figure 3) in 3% FBS in PBS were added to each well and incubated at 37°C for one-half hour. HRPO substrate was added and the
35 absorbance measured as described in section 2a above. MABs 4B5.6, SPL4A5, 8A2.1, 465C3D1 and A016-08, which showed minimum binding with the LDL-immobilized ELISA plate even

at 2 µg/mL antibody concentration, provided excellent binding of LDL when the MABs were immobilized on the plate. Figure 4 shows typical binding curves for 4B5.6, SPL4A5, 8A2.1, and 465C3D1. Based on these results, it is likely that the binding affinity of the MABs are dependent on the orientation of the lipoprotein particles, i.e. the MABs are LDL conformation dependent.

- 5 d. Competitive RIA on MAB Plate
- 10 In order to obtain additional data relating to the specificity of the MABs, competitive radioimmunoassays (RIA) were performed as follows. Iodine-125 labeled LDL (¹²⁵I-LDL) was prepared enzymatically using immobilized
- 15 lactoperoxidase and glucose oxidase (Enzymobeads, Bio-Rad) according to the standard procedure described in Tsao, et al. (1987) *J. Biol. Chem.* 257:15222-15228. The specific activity ranged between 1.87-2.60 µCi/µg. The ¹²⁵I-LDL sample was stored at 4°C in 0.1 M TRIS-saline pH 7.5 containing 10 mg/ml
- 20 lipid-free bovine serum albumin (BSA) (Armour CRG-7) and was used within 18 days after preparation. In the first series of experiments, the binding of ¹²⁵I-LDL to each MAB immobilized on Immulon 2 Removawell ELISA strips was evaluated. Typical binding curves of ¹²⁵I-LDL using MABs
- 25 2D8, 1D1 and MB16 are shown in Figure 5. The Removawell plates were prepared as follows. The concentrations of the MABs used in the preparation of the Removawell plates were exactly the same as described in section 2c above. One hundred microliters (100 µL) of each MAB solution in PBS
- 30 were added to each well and incubated at 37°C for one hour. The plates were washed five times with PBS and then blocked with 200 µL of 10% FBS in PBS. The plates were then washed five times with PBS. The lipoproteins were diluted in PBS to the following lipoprotein-cholesterol concentrations: LDL-
- 35 cholesterol, VLDL-cholesterol and HDL-cholesterol concentrations of 20 mg/dL; IDL-cholesterol concentration of 10 mg/dL; and Lp(a) at a Lp(a) total mass of 20 µg/dL. Fifty

microliters (50 μ L) of each lipoprotein solution were serially diluted in PBS in microtiter reaction wells blocked by 10% FBS in PBS. Fifty microliters (50 μ L) of 125 I-LDL (100,000 cpm) diluted in 3% (w/v) BSA in PBS were added to each well.

- 5 The contents from each well were transferred completely to respective MAB Removawell plates. The plates were incubated at room temperature on a rotator at 100 rpm for 20 hours. The plates were then washed eight times with PBS. Each well was then transferred to Falcon polystyrene tubes (12 x 75 mm) and the bound radioactivity was counted on an APEX automatic Y-counter. The background was subtracted to calculate the net binding. The competitive displacement curves for 4B5.6 are shown in Figure 6. The cross-
- 10

15

TABLE 3
COMPETITIVE BINDING OF MABs BY RIA

MAB	% Cross-Reactivity with LDL			
	VLDL	IDL	Lp(a)	HDL
B19	26	63	33	0
B02	80	58	9	0
8B3.5	42	61	44	0
8A6.6	100	12	<2	0
8A2.1	7	7	<2	0
465C3D1	15	50	8	0
457C4D1	83	69	4	0
464B1B3	153	345	92	0
464B1B6	73	393	110	0
MB16	19	21	6	0
2D8	50	27	12	6
1D1	42	63	14	0
5E11	42	27	12	6
4B5.6	7	18	2	0
SPL4A5	17	7	<1	0
A016-08	64	33	13	0
A016-09	56	43	8	0
A016-10	69	56	13	0

reactivities were determined for each MAB at 50% inhibition of binding using the equation in section 2b above. A summary of results are shown in Table 3.

The evaluation of the monoclonal antibodies described above indicates that at least two types of antigenic epitopes exist: one dependent mostly on the peptide sequence of the apo B fragments and the other dependent on the conformation dictated by the presence of associated lipids in the lipoproteins and also on the sizes of the particles. The results are summarized in Figure 7A. The antigenic epitopes of apo B fragments formed by thrombin which are known are shown in Figure 7B and the antigenic epitopes of apo B are known to bind the following MABs MAB 1D1 binds to the T4 fragment 1-1297. MAB 2D8 binds to the T3 fragment 1297-2177. MABs 8A2.1, 8A6.6 and 8B3.5 bind to the T3 fragment 1297-3249. MAB 5EII binds to the T3/T2 fragment 2488-3636. MAB MB47 binds to the LDL (B,E) receptor binding fragment 3350-3506 (Weisgraber et al (1988) Proc. Natl. Acad. Sci., USA 85:9758-9762). We found that all these MABs are highly cross-reactive with other apo B containing lipoproteins, such as VLDL and IDL. The MAB SPL4A5, for which the binding epitope of apo B is not known, appears to have higher affinity for LDL with smaller particle size as outlined in the U.S. Patent 4,619,895. This MAB was found to be less cross-reactive to VLDL (17%) and IDL (7%). MAB MB16 is known bind to the T2 fragment 4154-4189. We have determined that MAB MB16 had minimal cross-reactivity with VLDL (19%) and IDL (20%). MAB 4B5.6 is known to bind to the T2 fragment 3249-4536. We determined that MAB 4B5.6 had minimal cross-reactivity with VLDL (7%) and IDL (18%). Thus, MABs, which are specific for the apo B T2 fragment or sub-fragments thereof, will bind to the apo B T2 fragment and LDL, but will have low (less than 20%) cross-reactivity with VLDL, IDL and Lp(a). Such MABs would be useful in selectively binding LDL in the presence of other lipoproteins. MABs, which are specific for the apo B T3 fragment or sub-fragments thereof, can also selectively bind to LDL, with low (less than 20%) cross-reactivity with VLDL, IDL and Lp(a), as illustrated

by MAB 8A2.1 in Table 3. However, as will be shown later, MAB 8A2.1's LDL selectivity may be due to particle size because MAB 8A2.1 failed to bind to LDL particles from every plasma sample tested. On the other hand, MABs specific for apo B
5 fragments T4, T3/T2 and sub-fragments thereof will produce MABs which are cross-reactive with other lipoproteins.

Therefore, it is possible to generate LDL-specific MABs using specific peptide fragments of the apo B T2 fragment and possibly also the apo B T3 fragment. Figure 8 shows some
10 typical peptide fragments of apo B T2 fragment useful in generating LDL-specific MABs.

3. IMMOBILIZATION OF MONOCLONAL ANTIBODY TO SOLID PHASE

15 It was our intention to selectively capture LDL particles on the antibody coated solid phase and assay for the cholesterol in the bound LDL. Cholesterol or other lipids associated with lipoproteins are very hydrophobic. Therefore, it is desirable to use solid phases in an assay for cholesterol
20 which are hydrophilic. Moreover, the solid phase must have high binding capacity and should be non-porous to avoid preferential inclusion of lipoproteins in the porous solid phase. Also, since antibody is to be immobilized on the solid phase, the activity and the orientation of the immobilized antibody
25 must be substantially preserved. We selected CNBr-activated Sepharose 4B (Pharmacia LKB), carbolink hydrazide agarose beads (Pierce Chemicals), and Sulfolink coupling agarose beads (Pierce Chemicals) to demonstrate the feasibility of an LDL specific cholesterol assay. However, any other hydrophilic
30 solid phase, such as Trisacryl (IBF), HEMA-epoxy Bio Gel, HEMA vinylsulfone Bio Gel (Altech Associates), glycosylated silica gel or control porous glass, hydrophilic latex beads, other cellulosic materials etc. can also be used. Examples 4, 5, and 6 show the methods used in the covalent attachment of the
35 monoclonals antibody to CNBr-activated Sepharose 4B, carbolink hydrazide gel and sulfolink gel, respectively.

4. EVALUATION OF ANTIBODY IMMOBILIZED SOLID PHASES

The antibody immobilized solid phases were evaluated in terms of their binding efficiencies by incubating the solid 5 phases with purified LDL fractions from normal subjects and then determining the amount of LDL bound by measuring the amount of cholesterol in the bound solid phases. The cholesterol assay was performed using the reagents as described in Example 7. A typical cholesterol standard curve 10 is shown in Figure 9.

The protocol for the lipoprotein capture assays is described in Example 8. The efficiency of LDL capture on a Sepharose 4B matrix having MAB SPL4A5 bound thereto is shown in Table 4. The result shows that 90% or more LDL 15 particles are being captured on the antibody matrix. Using the same amount of MABs 4B5.6, 8A2.1, and MB16 on CNBr-activated Sepharose 4B, the LDL capture efficiencies were between 92%-98% for LDL having LDL-cholesterol concentrations ranging from about 6 mg/dL to about 24 mg/dL.

In order to investigate whether the other two antibody-matrices, namely hydrazide gel and sulfolink gel, are better than the CNBr-activated Sepharose 4B matrix, a comparative study was undertaken using approximately the same amount of 20

25

TABLE 4
EFFICIENCY OF LDL CAPTURE ON SPL4A5-SEPHAROSE

MAB Matrix* (μ L)	LDL** (mg/dL****)	% LDL Captured
50	6	72
50	12	83
100	6	90
100	12	92

* MAB Matrix concentration = 2.8 μ g/ μ L.

** 100 μ L sample size.

*** LDL concentration is the amount of LDL having 30 the listed LDL-cholesterol concentration.

TABLE 5
LDL CAPTURE EFFICIENCY OF SPL4A5 MATRICES

MATRIX (100 µL)	AMOUNT OF MAB (µg)	LDL* (mg/dL**)	% LDL Captured
Sepharose 4B	143	6	77
	143	12	78
	143	24	81
Hydrazide	133	6	55
	133	12	66
	133	24	70
Sulphydryl	117	6	60
	117	12	66
	117	24	66

* 100 µL sample size.

** LDL concentration is the amount of LDL having the listed
5 LDL-cholesterol concentration.

antibody on each gel matrix. The results of this study is shown in Table 5. Since the efficiency of LDL-capture in this experiment was lower than in Table 4, the study still clearly 10 demonstrates that the hydrazide gel and the sulfolink gel are not superior to Sepharose 4B. Therefore, Sepharose 4B was selected to demonstrate the new LDL-immunocapture assay. In all future experiments described herein, 100 µL of MAB-Sepharose 4B at an MAB (SPL4A5, 8A2.1, 4B5.6, or MB16) 15 concentration of 2.8 µg/µL were used.

We have shown in the competitive RIA (see Table 3) that the MABs SPL4A5, 8A2.1 and 4B5.6 have weak cross-reactivity with VLDL. Since it is important to know the effect of VLDL present in the plasma along with other lipoproteins in the 20 immunocapture assay, a normal plasma sample with known LDL-cholesterol concentration was used. The plasma was spiked with different amounts of purified VLDL from the same individual and the spiked samples were assayed for the LDL-cholesterol concentration using the present assay method. 25 The results are shown in Table 6. All three MABs provide

similar LDL-cholesterol concentration with increasing VLDL concentration. Also, the measured LDL-cholesterol concentrations increased with increasing VLDL concentrations and the LDL-cholesterol measurements were particularly 5 affected when the VLDL-cholesterol concentration exceed 50% of the LDL-cholesterol concentration. The concentration of VLDL-cholesterol in plasma in most plasma samples is usually less than 50% of the LDL-cholesterol concentration except in a few rare pathological states (such as type III and type IV 10 hypertriglyceridic patients). Generally, an LDL-cholesterol measurement can be affected by VLDL-cholesterol up to $\pm 10\%$ without affecting the clinical significance of the LDL-cholesterol measurement.

This experiment was done with one normal plasma 15 sample and since LDL particle sizes and compositions vary between individuals, the LDL-immunocapture assay was evaluated with a large number of individuals with varied lipoprotein profiles.

20

TABLE 6
EFFECT OF VLDL ON LDL-CHOLESTEROL MEASUREMENT

LDL-Chol. (mg/dL)	Spiked VLDL- Chol. (mg/dL)	% VLDL In LDL	LDL -Chol. (mg/dL) using MAB-Sepharose		
			SPL4A5	8A2.1	4B5.6
122	18	15	118	120	115
122	36	30	126	123	126
122	54	44	130	136	126
122	90	74	156	161	156
122	122	100	181	187	183

5. LDL-IMMUNOCAPTURE ASSAY

25 The protocol for the LDL-immunocapture assay is described in Example 9. The LDL-cholesterol concentrations obtained were correlated with the reference methods

ultracentrifugation (β -quantitation) and Friedewald calculation. The ultracentrifugation method for β -quantitation is described in Example 10. The Friedewald calculation method for quantitation is described in Example 11.

- 5 SPL4A5-Sepharose 4B Matrix: Thirty-four subjects were used in this study (See Table 7 for lipid profiles). The LDL-cholesterol concentrations determined by the two reference methods and the immunocapture assay are presented in Table 8. The correlations between the immunocapture 10 assay and the two reference methods are shown in Figure 10 (A and B). The results indicated that several samples (such as Nos. 15-19) had much lower LDL-cholesterol concentrations as measured by MAB SPL4A5-Sepharose as compared to both reference methods. This suggests that the MAB SPL4A5 alone 15 cannot capture all LDL particles of heterogeneous sizes present in these samples.

TABLE 7
LIPID PROFILES OF PLASMA SAMPLES

Sampl. No.	Total Chol. mg/dL	HDL- Chol. mg/dL	TRIG ¹ mg/dL	F.E. ² LDL- Chol. mg/dL	U.C. ³ LDL- Chol. mg/dL	VLDL- Chol. ⁴ mg/dL	Lp(a)- Chol. ⁵ mg/dL
1	138	22	83	99	97	21	0.5
2	181	28	333	86	86	63	1.1
3	128	47	102	61	61	14	1.8
4	119	51	32	62	62	10	15.6
5	104	37	48	57	64	6	15.4
6	183	42	98	121	124	18	19.3
7	187	27	194	121	122	39	18.8
8	158	39	78	103	93	26	1.0
9	128	48	106	59	73	7	7.1
10	116	38	41	70	75	3	2.0
11	157	39	191	80	92	26	4.7
12	117	28	51	79	82	7	5.3
13	142	68	37	66	62	15	7.6
14	179	41	127	113	103	35	5.8

39

15	150	51	85	82	88	10	2.1
16	122	33	50	79	81	18	10.0
17	184	45	132	113	100	38	2.5
18	161	77	94	65	68	28	1.2
19	115	23	77	76	84	8	4.7
20	127	65	117	39	35	34	1.2
21	141	31	171	76	95	15	4.8
22	172	45	70	113	121	16	8.6
23	154	78	68	51	50	22	2.3
24	119	33	51	76	78	8	3.1
25	135	41	114	71	86	8	3.1
26	135	53	53	70	60	22	8.5
27	169	47	235	75	83	39	1.4
28	127	56	83	54	60	11	2.8
29	112	48	49	55	37	17	13.0
30	166	54	35	105	106	7	4.1
31	160	53	145	78	71	36	0.8
32	215	29	187	155	154	32	9.9
33	234	54	108	168	169	12	4.6
34	216	45	122	146	136	35	17.6
35	161	30	109	109	108	37	3.2
36	196	54	67	128	116	35	12.9
37	172	45	105	105	106	48	1.4
38	195	39	198	114	132	24	0.9
39	160	41	74	104	109	14	1.0
40	216	58	126	133	133	22	4.6
41	173	52	148	92	83	39	0.6
42	162	54	115	85	92	25	4.5
43	193	79	90	96	100	14	2.0
44	149	44	61	93	97	8	11.3
45	170	62	92	81	68	40	0.6
46	173	84	114	66	76	16	0.7
47	304	53	298	191	170	88	28.0
48	273	47	220	188	184	28	1.8
49	261	52	166	176	146	63	0.8
50	179	63	90	98	93	26	5.7
51	229	46	132	157	152	43	5.4

52	224	39	152	152	149	46	2.0
53	208	40	201	128	140	28	2.0
54	267	37	122	189	175	55	16.9
55	189	51	78	122	103	38	0.4
56	225	60	110	143	134	27	0.4
57	208	79	51	119	121	8	2.0
58	172	77	44	86	78	19	1.0
59	152	57	43	87	87	13	1.6
60	254	78	66	163	147	31	6.5
61	194	51	140	115	104	59	1.2
62	172	59	117	89	78	44	0.4
63	165	59	117	104	83	33	3.6
64	193	53	61	114	105	54	14.0
65	151	57	66	81	59	36	5.2
66	200	33	115	144	137	58	1.6
67	241	32	470	115			
68	276	56	408	138			
69	295	37	259	206			
70	290	34	285	199			
71	310	43	595	148			

¹ TRIG = triglyceride concentration.

² F.E. = Friedewald Equation:

$$[\text{LDL-Chol}] = [\text{Total Chol}] - [\text{HDL-Chol}] - [\text{TRIG}/5].$$

³ U.C. = Ultracentrifuge β-quantitation:

$$\text{5} \quad [\text{LDL-Chol}] = [\text{d } > 1.006 \text{ Infranate-Chol}] - [\text{HDL-Chol}].$$

⁴ Calculated from U.C. LDL-Chol. values.

⁵ Calculated by multiplying total Lp(a) measured by Terumo ELISA by 0.3: $[\text{Lp(a)-Chol}] = 0.3[\text{Total Lp(a)}]$.

- 10 8A2.1-Sepharose 4B Matrix: The results are presented in Table 8 and the correlations between the immunocapture assay using MAB 8A2.1-Sepharose and the two reference methods are shown in Figure 11 (A and B). Here also lower LDL-cholesterol concentrations were obtained for some
15 samples as compared to the reference methods. This result also demonstrates that the MAB 8A2.1 alone cannot be used

for capturing all LDL particles of heterogeneous sizes expected to be present in many subjects.

- 4B5.6-Sepharose 4B Matrix: The LDL-cholesterol concentrations determined by the two reference methods and by the immunocapture assay using MAB 4B5.6-Sepharose are presented in Table 8. The correlations between the immunocapture assay using MAB 4B5.6-Sepharose and the reference methods are shown in Figure 12 (A and B). None of the LDL-cholesterol measurements made by the immunocapture assay were substantially lower than the reference method values. These results demonstrate that the MAB 4B5.6 is capable of capturing all LDL particles of heterogeneous sizes. The correlation with the ultracentrifugation method (correlation coefficient (r) = 0.95, slope 0.93) was found to be better than with Friedewald calculation method (r = 0.95; slope 0.86). This is not surprising because it is well-known that ultracentrifugation method is superior to the Friedewald calculation method due

20

TABLE 8
CORRELATION BETWEEN LDL-CHOLESTEROL ASSAYS

Samp. No.	LDL-Cholesterol (mg/dL)							
	F.E.1	U.C.2	F.E. - Lp(a)	U.C. - Lp(a)	I.C.3 4B5.6	I.C.3 MB16	I.C.3 SPL4	I.C.3 8A2.1
1	99	97	98	96	96	97	97	92
2	86	86	85	85	98	107	99	100
3	61	61	59	59	50	63	64	53
4	62	62	46	47	55	43	60	60
5	57	64	42	49	50	50	54	55
6	121	124	102	105	108	103	116	117
7	121	122	102	103	122	110	127	116
8	103	93	102	92	105	100	103	105
9	59	73	52	66	62	61	54	70
10	70	75	68	73	69	87	69	68
11	80	92	75	87	89	99	91	97
12	79	82	72	77	72	82	70	78

13	66	62	58	55	49	74	67	42
14	113	103	107	97	107	120	130	101
15	82	88	80	86	66	79	60	56
16	79	81	69	71	72	81	36	30
17	113	100	110	97	83	96	45	39
18	65	68	64	67	63	85	32	26
19	76	84	71	79	59	72	43	33
20	39	35	38	34	34	50	27	32
21	76	95	71	91	75	78	87	81
22	113	121	104	112	107	115	120	
23	51	50	49	48	59	67	32	
24	76	78	73	75	75	70	73	
25	71	86	68	83	68	77	86	
26	70	60	68	52	62	59	74	
27	75	83	74	82	98	118	94	
28	54	60	51	57	57	58	52	
29	55	37	43	25	39	38	48	
30	105	106	101	102	91	103	107	
31	78	71	77	70	70	76	79	
32	155	154	145	144	146	144	117	
33	168	169	163	164	162	144	194	
34	146	136	129	119	130	126	170	
35	109	108	106	105	91	103		
36	128	116	115	103	103	126		
37	105	106	104	105	106	112		
38	114	132	113	131	136	114		
39	104	109	103	108	108	111		
40	133	133	129	129	135	120		
41	92	83	91	82	103	104		
42	85	92	81	88	100	90		
43	96	100	94	98	91	106		
44	93	97	82	86	95	117		
45	81	68	80	67	79	80		
46	66	76	65	75	70	80		
47	191	170	163	142	149	221		
48	188	184	186	183	185	176		
49	176	146	175	145	154	191		

50	98	93	92	88	91	94		
51	157	152	152	147	140	145		
52	152	149	150	147	145	162		
53	128	140	126	138	125	133		
54	189	175	172	158	157	174		
55	122	103	122	103	106	110		
56	143	134	143	134	134	129		
57	119	121	117	119	100	99		
58	86	78	85	77	73	70		
59	87	87	85	85	77	88		
60	163	147	156	140	128	148		
61	115	104	113	103	105	118		
62	89	78	89	78	93	98		
63	104	83	100	80	80	79		
64	114	105	100	91	89	115		
65	81	59	76	54	65			
66	144	137	142	134	140			
67	115				106			
68	138				121			
69	206				194			
70	199				177			
71	148				145			

¹ F.E. = Friedewald Equation:

$$[LDL-Chol] = [Total Chol] - [HDL-Chol] - [TRIG/5].$$

² U.C. = Ultracentrifuge β -quantitation:

$$[LDL-Chol] = [d > 1.006 Infranate-Chol] - [HDL-Chol].$$

³ I.C. = Immunocapture assay using the named MAB.

⁴ SPL = MAB SPL4A5

to the inaccuracy incurred for samples with triglyceride concentration over 300 mg/dL.

- 10 The LDL-cholesterol concentrations measured by both reference methods are actually not a true measurement of LDL-cholesterol but instead are a mixture of LDL-, IDL-, and Lp(a)-cholesterol concentrations. Although these three lipoprotein particles are considered to be potential atherogenic markers and all previous data base on LDL-
- 15

cholesterol values are based on these two reference methods, a correction for IDL and Lp(a) should be made in order to obtain a better correlation between the disease state and the true LDL-cholesterol concentrations. No reliable method of 5 IDL quantitation is presently available except through the lengthy ultracentrifugation techniques.

A number of methods for quantitation of Lp(a) mass are known. We have used a commercial ELISA kit (TEMUMO Medial Corporation, Elkton, MD) to estimate the Lp(a) mass and the 10 concentrations of cholesterol are then calculated by multiplying the total Lp(a) mass with 0.3, because 30% is generally assumed to be the cholesterol content of Lp(a). The Lp(a)-subtracted LDL-cholesterol concentration of the two reference methods are presented in Table 8. The LDL- 15 cholesterol concentrations minus the Lp(a)-cholesterol contributions were correlated with the LDL-cholesterol concentrations obtained by the present immunocapture assay using MAB 4B5.6-Sepharose and are shown in Figure 13 (A and B). The correlation between immunocapture assay using MAB 20 4B5.6-Sepharose and ultracentrifugation method has an intercept of 0.96 a slope of 0.96. The correlation between immunocapture assay using MAB 4B5.6-Sepharose and Friedewald method has a correlation coefficient (r) of 0.95 and a slope of 0.89. Thus, the correlation of the present assay 25 method becomes better after correcting for Lp(a)-cholesterol in the LDL-cholesterol concentrations determined by the two reference methods (see Figures 12 and 13).

The present assay method is virtually independent of the triglyceride concentration (tested up to 470 mg/dL, see Table 30 7) and VLDL-cholesterol (tested up to 88 mg/dL, see Table 8). The results are shown in Figures 14 (A and B) and 15 (A and B). The Y-axes in Figures 14A and 15A represent the ratio of LDL-cholesterol concentrations determined by the present method and ultracentrifugation method. The Y-axes in Figures 14B and 35 15B represent the ratio of LDL-cholesterol concentrations determined by the present method and ultracentrifugation method corrected for the Lp(a)-cholesterol contribution. The

TABLE 9

LDL-CHOLESTEROL IN LIPID LOWERING DRUG TREATED PATIENTS

Sample No.	Total Chol. mg/dL	HDL-Chol. mg/dL	TRIG ¹ mg/dL	F.E. ² LDL-Chol. mg/dL	U.C. ³ LDL-Chol. mg/dL	I.C. ⁴ LDL-Chol. mg/dL
72	205	37	275	113	112	125
73	210	26	425	N/A	78	93
74	218	47	170	137	121	132
75	257	45	222	168	168	163
76	249	35	136	187	169	174
77	151	38	230	67	56	76
78	299	43	175	221	224	209
79	323	65	430	N/A	204	161
80	180	30	242	102	100	103
81	275	40	177	200	191	174
82	289	41	320	184	173	179
83	332	61	140	209	219	184
84	208	45	129	137	131	128
85	225	49	193	137	132	123
86	201	44	114	134	123	115
87	220	69	96	119	118	112
88	436	46	336	325	166	203
89	341	43	701	N/A	147	186
90	798	53	679	N/A	329	451
91	361	27	903	N/A	195	164

¹ TRIG = triglyceride concentration.

² F.E. = Friedewald Equation:

[LDL-Chol] = [Total Chol] - [HDL-Chol] - [TRIG/5].

³ U.C. = Ultracentrifuge β-quantitation:

[LDL-Chol] = [d >1.006 Infranate-Chol] - [HDL-Chol].

⁴ I.C.= Immunocapture assay using MAB 4B5.6.

10 N/A = F.E. LDL-cholesterol cannot be used for individuals with high TRIG levels (greater than about 400 mg/dL).

X-axes in Figures 14 and 15 represent triglyceride and VLDL concentration, respectively.

The present assay method for LDL-cholesterol was evaluated with patient samples who are on lipid lowering drugs. The results are presented in Table 9.

MB16-Sepharose 4B Matrix: The LDL-cholesterol concentrations measured by the immunocapture assay using MAB MB16-Sepharose and by the two reference methods are presented in Table 8. Figure 16 (A and B) shows the correlations between the immunocapture assay using MAB MB16-Sepharose and ultracentrifugation and Friedewald methods. The correlation between immunocapture assay using MAB MB16-Sepharose and ultracentrifugation method has a correlation coefficient (*r*) of 0.91 a slope of 0.96. The correlation between immunocapture assay using MAB MB16-Sepharose and Friedewald method has a correlation coefficient (*r*) of 0.93 and a slope of 0.90. Figure 17 (A and B) shows the correlations after the Lp(a)-cholesterol contribution has been subtracted from the two reference methods. In this study also, the correlations become better after Lp(a)-cholesterol correction similar to that observed for the MAB 4B5.6-Sepharose immunocapture assay.

The immunocapture assay using MAB MB16-Sepharose showed no dependency on the triglyceride concentration (tested up to 333 mg/dL; see Table 7). The results are shown in Figure 18 (A and B). However, the immunocapture assay using MAB MB16-Sepharose showed some dependency on VLDL-cholesterol (see Table 7). The results are shown in Figure 19 (A and B). This dependency is not unexpected because MAB MB16 showed about 19% cross-reactivity with VLDL compared to only 7% for MAB 4B5.6 in the competitive RIA (see Table 3).

The Y-axes in Figures 18A and 19A represent the ratio of LDL-cholesterol concentrations determined by the present method and ultracentrifugation method. The Y-axes in Figures 18B and 19B represent the ratio of LDL-cholesterol concentrations determined by the present method and ultracentrifugation method corrected for the Lp(a)-

cholesterol contribution. The X-axes in Figures 18 and 19 represent triglyceride and VLDL concentration, respectively.

6. CHOLESTEROL BINDING AGENTS

5

a. LDL-Cholesterol Standards

Plasma samples of known LDL-cholesterol concentrations as determined by reference methods were used to generate standard curves. Standards with LDL-cholesterol 10 concentrations of 74, 101, 135 and 207 mg/mL were prepared by diluting the plasma samples with 1% alkali-treated casein in 20 mM phosphate buffered saline (PBS) at pH 7.4.

15

b. Preparation of Digitonin-Peroxidase Conjugates

Digitonin (2.5 mg/mL in water) (water soluble containing 50% digitonin and sodium deoxycholate commercially available from Sigma Chemical Company, St. Louis, MO) was oxidized with sodium meta-periodate (a solution of 1.68% w/v periodate in water was added to the 20 digitonin solution to a final concentration of 0.02 M periodate) (Tschesche and Wulff (1963) Tetrahedron 19:621-634). The mixture was stirred at 4°C for one hour and then dialyzed against 20 mM phosphate buffered saline (PBS), pH 8.0, at 4°C overnight. The oxidized digitonin was then mixed with 25 ethylenediamine (a solution of 0.25 M ethylenediamine in 20 mM PBS, at pH 8.0, was added to the oxidized digitonin solution to a final concentration of 0.05 M ethylenediamine) and incubated at 4°C. The mixture was then reduced by two additions of 100 µL of 4 mg/mL sodium borohydride in 0.1 N 30 sodium hydroxide (i.e. 100 µL of the sodium borohydride solution per 30 mg of digitonin), after 30 minutes and after 60 minutes. After incubating at 4°C for two hours, the mixture was dialyzed against 0.01 M carbonate buffer, pH 9.5, at 4°C overnight.

35

Five milligrams (5 mg) of horseradish peroxidase (HRPO) (155 Ku/mg, commercially available from Amano International) were dissolved in water to a final

concentration of 4 mg/mL HRPO. The HRPO was oxidized by adding 50 μ L of a freshly prepared solution of 0.2 M sodium meta-periodate per milligram of HRPO to the HRPO solution and incubating the mixture in the dark at room temperature
5 for 20 minutes. The mixture was then dialyzed against 2 liters of 1 mM acetate buffer, pH 4.5, at 4°C for 4 hours.

The ethylenediamine derivatized digitonin solution and the oxidized HRPO solution were mixed in digitonin:HRPO weight ratios of 1:5 and 1:10. To each reaction was added 0.2
10 M carbonate buffer, pH 9.5 (50 μ L buffer/mg digitonin), and the pH was adjusted to 9.5 as necessary. The reactions were stirred in the dark at room temperature for two hours and 100 μ L of sodium borohydride solution (4 mg/mL in water) was added to each reaction. After incubating for two hours at 4°C,
15 the reactions were dialyzed against 20 mM PBS, pH 7.4, at 4 °C overnight. To each mixture was added 5% (w/v) of sodium deoxycholate in water (one-tenth the volume of the dialyzed solutions) and fatty-acid free bovine serum albumin (to a final concentration of 5 mg/mL). The solutions were then sterile
20 filtered through a 0.22 micro filter (Coaster Labs) and stored at -20°C.

c. Preparation of Tomatine-Peroxidase Conjugates

Tomatine-HRPO conjugates in weight ratios of 1:5 and
25 1:10 were prepared from tomatine (Sigma Chemical Company, St. Louis, MO) (Reichstein (1962) Agnew Chem. 74:887-918) dissolved in 1% (w/v) aqueous sodium deoxycholate using the same procedure described above for digitonin-HRPO conjugates (paragraph 6.b.).

30

d. Preparation of Amphotericin-Peroxidase Conjugates

Amphotericin-HRPO conjugates in weight ratios of 1:5 and 1:10 were prepared from 1 mg amphotericin B (80% pure, Sigma Chemical Company, St. Louis, MO) suspended in 1 mL of
35 0.01 M bicarbonate buffer using the same procedure described above for digitonin-HRPO conjugates (paragraph 6.b.). The conjugates were sterile filtered using 0.45 micro filters.

e. Preparation of Anti-Cholesterol Antibodies

3-Hydroxycholan-5-en-24-oic acid (commercially available from Steraloids Inc., Wilton, NH) was reacted with 5 N-hydroxysuccinimide and 1,3-dicyclohexylcarbodiimide to form an active ester under typical reaction conditions. The active ester was reacted with 6-aminohexanoic acid to form 6-(3-hydroxycholan-5-en-24-carbonylimino)hexanoic acid. This carboxylic acid was reacted with N-hydroxysuccinimide 10 and 1,3-dicyclohexylcarbodiimide to form a second active ester which was reacted with bovine serum albumin to form the immunogen. The immunogen was purified on a Sephadex G-25 column using standard purification techniques.

3-Hydroxycholan-5-en-24-oic acid may be coupled 15 directly to natural or synthetic proteins to form immunogens useful in the preparation of both polyclonal and monoclonal anti-cholesterol antibodies. Other amino acid linking groups like aminohexanoic acid, such as aminoacetic acid, aminopropanoic acid, aminoheptanoic acid and the like, may be 20 used to prepare useful immunogens. Also, diamino linking groups, such as ethylenediamine and the like, can be used to prepare useful immunogens. Linker arms of the general formula X-(CH₂)_n-Y, where X is a primary or secondary amine or a carboxylic acid group, Y is a primary or secondary amine 25 and n = 1-10, are useful for the preparation of anti-cholesterol producing immunogens. The steroid with such a linking group can be coupled to natural or synthetic proteins to form immunogens useful in the preparation of both polyclonal and monoclonal anti-cholesterol antibodies.

The preparation of polyclonal and monoclonal antibodies using immunogens is well known in the art (Tijssen, "Laboratory Techniques In Biochemistry And Molecular Biology: Practice and Theory of Enzyme Immunoassays", Vol. 15, Elsevier, New York (1985)).

35 Polyclonal antibodies were preferably raised in rabbits, but other animals, such as sheep, pigs, mice, rats, goats, donkeys and the like, can also produce suitable antibodies.

Antibody binding was tested by enzyme-linked immunosorbent assay. Cholesterol antigens, such as HDL, LDL, VLDL and IDL particles in 0.15 M saline, cholesterol in 95% ethanol (0.25 µg/well) and cholesterol esters in hexane (0.25 µg/well),
5 were absorbed in polystyrene microtiter plate wells. The wells were then blocked with 10% (v/v) fetal calf serum or 1% (w/v) casein solutions. The antibody to be tested was incubated in the well and the well was washed with 0.05% (w/v) Tween 20 in 20 mM PBS, pH 7.0. Enzyme labelled anti-
10 antibody antibody, such as goat anti-rabbit IgG conjugated to HRPO, was used to detect the presence of antibody bound to the cholesterol antigen absorbed in the well. Rabbit antibody raised against the 6-(3-hydroxycholan-5-en-24-carbonylimino)hexanoic acid hapten coupled to BSA bound to
15 cholesterol and cholesterol esters, but showed preferential binding to lipoprotein cholesterol particles in the order: HDL ≈ VLDL > LDL > IDL.

f. Preparation of Antibody-Peroxidase Conjugates
20 Anti-cholesterol Antibody-HRPO conjugates were prepared as follows. Anti-cholesterol rabbit polyclonal antibody was purified by double precipitation with 33% saturated ammonium sulfate. The antibody (2.7 mg of IgG) was coupled to HRPO (1.44 mg) using the procedure described
25 above for digitonin-HRPO conjugates (paragraph 6.b.).

g. Preparation of Digitonin-Phosphatase Conjugates
Calf intestine alkaline phosphatase (AP) (10 mg/mL)
was mixed with sodium meta-periodate (4.28 mg/mL) in 0.2 M
30 sodium acetate, pH 4.5, and stirred at room temperature in the dark for three hours. The mixture was desalted on a Pharmacia PD-10 column which was pre-equilibrated with a solution of 10 mM sodium acetate, 0.1 M sodium chloride, 1 mM magnesium chloride and 0.1 mM zinc chloride at pH 4.5.
35 The oxidized alkaline phosphatase was then mixed with the ethylenediamine derivatized digitonin (0.6 mL of a 1.67 mg/mL solution in 20 mM PBS, pH 7.4) prepared above

- (paragraph 6.b.) in 20 mM PBS, pH 7.4 in a digitonin:phosphatase weight ratio of 1:5. To the mixture was added 90 μ L of 1 M bicarbonate buffer, pH 9.5 and the mixture was incubated at room temperature for 16 hours in the dark.
- 5 Thirty microliters of sodium borohydride (5 mg/mL in 0.1 M bicarbonate buffer, pH 9.5) was added to the reaction and the reaction was incubated at 4°C for 4 hours. The reaction was then dialyzed against 2 liters of a solution of 0.05 M TRIS, 0.1 M sodium chloride, 1 mM magnesium chloride, 0.1 mM zinc
- 10 A solution of 5% sodium deoxycholate in water (one-tenth the volume of the dialyzed material) and fatty-acid free BSA were added to make the BSA final concentration 5 mg/mL. The digitonin-AP conjugate was sterile filtered through a 0.22
- 15 micro filter and stored at -20°C.

h. Preparation of Other Conjugates

Tomatine-alkaline phosphatase conjugates were prepared in tomatine:phosphatase weight ratios of 1:5 and

20 1:10 according to the digitonin-AP conjugate procedure (paragraph 6.g.). Amphotericin-alkaline phosphatase conjugates were prepared in amphotericin:phosphatase weight ratios of 1:5 and 1:10 according to the digitonin-AP conjugate procedure (paragraph 6.g.). Antibody-alkaline phosphatase

25 conjugates were prepared from rabbit anti-cholesterol IgG antibody (2.4 mg IgG) and AP (7.2 mg) according to the digitonin-AP conjugate procedure (paragraph 6.g.).

i. Peroxidase Conjugate Binding to LDL

30 Maxisorb Nunc Immuno plates were coated with 100 μ L of pure LDL (5 μ g/mL cholesterol concentration) in 20 mM PBS, pH 7.4, at 37°C for 30 minutes. After blocking the non-specific binding sites with 200 μ L of 5% BSA in 20 mM PBS, pH 7.4, at 37°C for one hour, the plates were washed five

35 times with 0.05% Tween 20 in 20 mM PBS, pH 7.4 (PBS-Tween). Then each conjugate was titrated from 5 μ g/mL in 2% BSA in 20 mM PBS, pH 7.4 (100 μ L in each well). The plates

were incubated at 37°C for one hour and washed eight times with PBS-Tween. o-Phenylenediamine (OPD) (100 µL of a standard solution prepared from one OPD tablet/5 mL citrate buffer, pH 6; both commercially available from Abbott

- 5 Laboratories, IL) was added to the wells. After incubation for 5 minutes, the color reaction was stopped with 100 µL of 1 N sulfuric acid. The plates were read at 490 nm on a microplate reader (Bio-Tek). At a conjugate concentration of 1.25 µg/mL, the following absorbances were observed: digitonin-HRPO
10 (1:5) = 2.2; digitonin-HRPO (1:10) = 1.23; tomatine-HRPO (1:5) = 1.2; tomatine-HRPO (1:10) = 1.35; amphotericin B-HRPO (1:5) = 0.2; and amphotericin B-HRPO (1:10) = 0.18. At a conjugate concentration of 10 µg/mL, amphotericin B-HRPO (1:5 or 1:10) gave an absorbance of 0.8. Rabbit antibody-HRPO conjugate
15 gave an absorbance of 0.6 at a conjugate concentration of 1.25 µg/mL and a 1.70 absorbance at a conjugate concentration of 10 µg/mL.

j. Phosphatase Conjugate Binding to LDL

- 20 Maxisorb Nunc Immuno plates were coated with 100 µL of pure LDL (5 µg/mL cholesterol concentration) in 20 mM PBS, pH 7.4, at 37°C for 30 minutes. After blocking the non-specific binding sites with 200 µL of 5% BSA in 20 mM PBS, pH 7.4, at 37°C for one hour, the plates were washed five
25 times with 50 mM TRIS, 150 mM sodium chloride, 0.1% sodium azide and 0.05% Tween 20, pH 7.4 (TRIS-Tween). Then each conjugate (100 µL in each well) was titrated from 20 µg/mL in 1% alkali-treated casein in 50 mM TRIS, 100 mM sodium chloride, 1 mM magnesium chloride, 0.1 mM zinc chloride, 0.1%
30 sodium azide, pH 8.0 (dilution buffer). The plates were incubated at 37°C for one hour and washed eight times with TRIS-Tween. p-Nitrophenolphosphate (100 µL of 2 mg/mL in dilution buffer) was added to each well. After incubation at room temperature for 16 minutes, the color reaction was
35 stopped with 100 µL of 1 N sodium hydroxide. The plates were then read at 405 nm on a microplate reader. At a conjugate concentration of 10 µg/mL, the following absorbances were

observed: digitonin-AP (1:5) = 1.52; digitonin-AP (1:10) = 1.4; tomatine-AP (1:5) = 1.55; tomatine-AP (1:10) = 1.65; and amphotericin B-AP (1:5 OR 1:10) = 0.15. Rabbit antibody-AP conjugate gave an absorbance of 0.7 at a conjugate concentration of 10 µg/mL and a 0.97 absorbance at a conjugate concentration of 20 µg/mL.

5 k. Anti-LDL Coated Plates

The LDL specific monoclonal antibody 4B5.6 was diluted 10 in 20 mM PBS, pH 7.4, to a final concentration of 5 µg/mL. One-hundred microliters of the solution was added to each well of Maxisorb Nunc Immuno plates and incubated at room temperature with gentle shaking for two hours. The plates were washed five times with PBS-Tween and then blocked 15 with 200 µL of 5% BSA in 20 mM PBS by incubation at 37°C for one hour. The plates were stored at 4°C with plastic sealers. Before use, the plates were washed five times with PBS-Tween for HRPO conjugates and TRIS-Tween for AP conjugates.

20

I. LDL-Cholesterol Standard Curves

LDL-cholesterol standards (100 µL/well in duplicate) were incubated in the 4B5.6 plates (paragraph 6.k.) at 37°C for one hour. After washing the plates five times with PBS-Tween, 100 µL of digitonin-HRPO conjugate at 0.4 µg/mL in 1% casein in PBS or at 1.25 µg/mL in 1% casein in PBS was added to each well and incubated at 37°C for one hour. The plates were washed with PBS-Tween eight times. o-Phenylenediamine (OPD) (100 µL of a standard solution prepared from one OPD tablet/5 mL citrate buffer, pH 6; both commercially available from Abbott Laboratories, IL) was added to the wells. After incubation for 5 minutes, the color reaction was stopped with 100 µL of 1 N sulfuric acid. The plates were read at 490 nm on a microplate reader (Bio-Tek). Standard curves (absorbance vs. LDL-cholesterol concentration) were then prepared from the results. Standard

curves were also prepared with the tomatine-HRPO conjugates.

TABLE 10

5 CORRELATION BETWEEN LDL-CHOLESTEROL ASSAYS

Samp. No.	Total Chol. mg/dL	TRIG ¹ mg/dL	LDL-CHOLESTEROL (mg/dL) ⁴					
			F.E. ²	U.C. ³	DIG- HRPO	DIG- AP	TOM- HRPO	TOM- AP
201	255	77	192	183	183	191	189	191
202	143	49	83	80	94	93	92	73
203	141	40	74	70	73	74	75	74
204	198	53	123	116	108	110	108	109
205	160	52	89	85	113	94	92	85
206	201	82	144	142	134	130	136	136
207	167	45	102	98	102	97	101	99
208	197	127	135	130	138	137	133	132
209	247	119	167	164	162	165	162	158
210	186	83	116	112	103	120	122	118
211	230	93	160	157	167	157	157	164
212	237	243	154	160	190	175	190	199
213	280	164	202	197	206	207	207	211
214	168	79	114	114	121	119	122	122
215	215	187	155	154	143	139	146	147
216	216	122	146	136	138	152	152	155
217	162	148	85	92	130	129	144	133
218	149	61	93	97	111	129	142	124
219	170	92	81	68	132	129	130	123
220	173	114	70	76	113	95	89	99
221	273	220	188	184	135	145	137	143
222	179	90	98	93	89	108	93	90
223	229	132	157	152	147	156	139	152
224	224	152	152	149	135	126	128	122
225	267	122	189	175	158	167	156	145
226	189	78	122	103	117	131	121	132
227	225	110	143	134	141	166	141	153
228	208	51	119	121	120	115	131	130

229	152	43	87	87	109	118	118	117
230	354	66	163	143	162	179	134	167
231	194	140	115	104	96	110	123	117
232	172	117	89	78	98	93	109	94
233	193	61	114	105	133	121	148	129
234	172	51	86	78	89	108	111	80
235	218	170	137	121	133	128	161	129
236	257	222	168	168	158	156	205	163
237	151	230	67	56	62	65	82	63
238	299	175	221	224	165	194	205	138
239	323	430		204	133	164	163	122
240	180	242	102	100	96	120	107	92
241	275	177	200	191	190	194	200	185
242	289	320	184	173	181	167	183	160
243					164	132	185	161
244	332	140	209	219	189	213	205	203
245	208	129	137	131	110	127	126	127
246	225	193	137	132	110	126	140	130
247	210	114	134	123	132	153	143	138
248	220	96	119	118	91	107	83	86
249					128	128	185	127
250	117	51	79	82	83	94	54	82
251	172	70	113	121	132	131	137	135
252	436	336		166	262	212	265	235
253	345	328		115	122	125	106	143
254	337	468		99	93	101	69	113
255	341	701		147	197	164	235	170

¹ TRIG = triglyceride concentration.

² F.E. = Friedewald Equation:

$$[\text{LDL-Chol}] = [\text{Total Chol}] - [\text{HDL-Chol}] - [\text{TRIG}/5].$$

³ U.C. = Ultracentrifuge β -quantitation:

⁵ $[\text{LDL-Chol}] = [\text{d} > 1.006 \text{ Infranate-Chol}] - [\text{HDL-Chol}].$

⁴ DIG-HRPO = digitonin-HRPO conjugate based assay; DIG-AP = digitonin-AP conjugate based assay; TOM-HRPO = tomatine-HRPO conjugate based assay; and TOM-AP = tomatine-AP conjugate based assay.

Standard curves were also prepared with the digitonin-AP and tomatine-AP conjugates using the same procedure except that the TRIS-Tween wash, the dilution buffer and p-nitrophenolphosphate substrate (100 µL of 2 mg/mL in dilution buffer) were used as in paragraph 6.j. A 16 minute substrate incubation was used and the reaction was stopped with 100 µL of 1 N sodium hydroxide. The absorbances were read at 405 nm.

10 m. Evaluation of LDL-Cholesterol Sandwich Assay

Plasma samples in ethylenediaminetetraacetic acid (EDTA) were collected from normal individuals and patients. The samples were frozen at -20°C until used. Thawed samples were not used after two days storage at 4°C. The samples 15 were diluted 600-fold in 1% casein in PBS and assayed for LDL-cholesterol using the procedures of paragraph 6.l. wherein the diluted samples were used in place of the standards. Along with the samples, standards were also assayed in duplicate as before. For each microtiter plate, a standard 20 curve was generated and the values of the samples were determined using a point-to-point fitted computer program. The LDL-cholesterol measurements of the samples are shown in Table 10.

These results demonstrate the efficacy of the present 25 invention. The present invention is suitable for quantitating cholesterol and cholesterol esters associated with lipoprotein particles by the use of lipoprotein specific antibodies. The following more detailed examples are intended to further illustrate the present invention.

30

EXAMPLE 1

PURIFICATION OF MONOCLONAL ANTIBODIES

Purification of the monoclonal antibodies was performed 35 on Protein A-Sepharose 4B columns (Pharmacia LKB). The IgG fractions were first precipitated with 50% ammonium sulfate and the precipitate was re-dissolved and dialyzed against 20

mM phosphate buffered saline (PBS), pH 7 4°C. The dialyzed sample was diluted with an equal volume of 1.5M glycine in 3M sodium chloride at pH 8.9 (binding buffer) and loaded onto a Protein A column. A column size of 1.25 mL/mL of ascites was
5 used in the purification process. The flow rate during sample loading was maintained at about 0.5 mL/minute. The column was washed with binding buffer until the absorbance at 280 nm is ≤ 0.02. The bound IgG antibody was then eluted sequentially with 100 mM citrate buffer, pH 6 (for IgG₁), pH 5 (for IgG_{2a})
10 and pH 4 (for IgG_{2b}). Ten milliliters of each elution buffer was used for each milliliter of protein A in the column. The column was regenerated by washing with 100 mM citrate buffer, (pH 3) until the absorbance at 280 nM is ≤0.02 and then re-equilibrated with the binding buffer. Each column was used at
15 least five times without any loss of binding affinity.

EXAMPLE 2

PREPARATION OF LIPOPROTEIN FRACTIONS

20 Blood samples from normal fasting subjects were collected into ethylenediaminetetraacetic acid (EDTA) and the red blood cells were removed by centrifugation. The plasma samples were then analyzed for Lp(a) using TERUMO ELISA kit. Plasma samples containing less than 1 mg/dL Lp(a)-cholesterol
25 were selected for the purification of VLDL, IDL, LDL and HDL. Lipoprotein subtractions were prepared in a Beckman Ultracentrifuge with a SW 40 Ti rotor by successive ultracentrifugation at 4°C (Havel et al. (1955) *J. Clin. Invest.* 34:1345-1355). VLDL was collected at a density of about d
30 1.0006 g/mL; IDL was collected at a density range of about d 1.006-1.019 g/mL; LDL was collected at a density range of about d 1.019-1.050 g/mL; and HDL was collected at a density range of about d 1.080-1.225 g/mL. All fractions were isolated by a tube-slicing technique. The lipoprotein fractions were
35 dialyzed exhaustively against 0.15 M sodium chloride containing 0.1% EDTA and 0.1% sodium azide, pH 7.4 at 4°C. IDL, LDL and HDL fractions were sterile filtered through 0.2 micron

and VLDL through 0.45 micron membrane filters (Nalgene) and stored at 4°C. Lipoprotein (a) was isolated from plasma samples with Lp(a)-cholesterol concentrations more than 15 mg/dL on a lysine-Sepharose column (Fless and Scanu, 5 *Arteriosclerosis* (1987) 7:505A). The purity of each lipoprotein fraction was evaluated by electrophoresis under non-denaturing polyacrylamide gradient gel electrophoresis (Lefevre et al. (1987) *J. Lipid Res.* 28:1495-1509). Gradient slab gels, 2-16% and 4-30% and electrophoresis apparatus GE-24 (Pharmacia 10 LKB) were used in the analysis. The lipoprotein fractions containing no cross-contamination were used in the studies.

EXAMPLE 3

PREPARATION OF PEROXIDASE CONJUGATE OF ANTI-LDL

15 MONOCLONAL ANTIBODY

Horseradish peroxidase (1 mg = 155 Ku, Amano International) was dissolved in water (250 µL) and oxidized with freshly prepared 0.2 M sodium m-periodate (50 µL) at 20 room temperature in the dark for 20 minutes. The oxidized peroxidase was then dialyzed against 2 liters of 1 mM acetate buffer (pH 4.5) at 4°C for four hours. Monoclonal antibody B06 (1.9 mg/mL), which was dialyzed against 0.01 M carbonate buffer (pH 9.5) at 4°C, was treated with 20 µL of 0.2 M 25 carbonate buffer (pH 9.5). The antibody and the dialyzed peroxidase were then mixed at room temperature in the dark for two hours. To this mixture 24 µL of freshly prepared sodium borohydride (Aldrich, 4 mg/mL in water) was added and then incubated at 4°C in the dark for two hours. The 30 peroxidase-antibody conjugate was then dialyzed against two liters of 20 mM phosphate buffered saline (pH 7.4) at 4°C and stored at -20°C in small aliquots.

The binding curves of B06-peroxidase conjugate to lipoproteins are shown in Figure 3. A Maxisorb Nunc Immuno 35 plate was coated with 100 µL of different lipoproteins by incubation at 37°C for 1/2 hour. After blocking the non-specific sites with 200 µL of 10% FBS in PBS at 37°C for one

hour, and washing five times with PBS-Tween 20, 100 µL of B06-peroxidase conjugate (0.6 µg/mL diluted in 3% FBS in PBS) was added to each well. The plate was incubated at 37°C for 1/2 hour, washed eight times with PBS-Tween 20. One hundred 5 microliters of OPD substrate solution was added to each well. After incubation at room temperature for five minutes, the color reaction was stopped with 100 µL of 1N H₂SO₄. The plate was then read at 490 nm on a microplate reader.

10 **EXAMPLE 4**

COVALENT ATTACHMENT OF MONOCLONAL ANTIBODY TO CNBr-ACTIVATED SEPHAROSE 4B

One gram of CNBr-activated Sepharose 4B (Pharmacia 15 LKB) was suspended in about 15 mL of 1 mM HCl. The gel was then transferred to a coarse-porosity sintered-glass funnel and washed with about 200 mL of 1 mM HCl. The gel was then washed with 25 mL of 0.1 M carbonate buffer in 0.5 M sodium chloride, pH 8.3 (coupling buffer). A gentle vacuum was 20 applied to remove the buffer. The moist gel cake was then transferred to a glass tube with a screw-capped stopper. Monoclonal antibody (10 mg, concentration 0.5 to 1 mg/mL), which was dialyzed against the coupling buffer at 4°C, was then added to the gel. The mixture was then mixed gently end-over-end using an infiltration wheel at 4°C for 20 hours. The 25 supernatant was checked by measuring the absorbance at 280 nm for the unbound antibody. For all the monoclonal antibodies used here, more than 95% were bound to the gel. The gel was then transferred to a coarse-porosity sintered-glass funnel, washed with 50 mL of the coupling buffer and 25 mL of 0.1 M TRIS-HCl buffer, pH 8.0 (blocking buffer). The gel was then transferred to a glass tube, and mixed with 10 mL of the blocking buffer at room temperature for two hours. The 30 antibody-immobilized gel was then washed with three cycles of alternating pH. Each cycle consisted of a wash with acetate buffer (0.1 M, pH 4) containing sodium chloride (0.5 M) followed by a wash with TRIS buffer (0.1 M, pH 8) containing 35

sodium chloride (0.5 M). The final wash was done with 100 mL of TRIS-HCl buffer (0.05 M pH 7.4) containing sodium chloride (0.15 M) and sodium azide (0.01%) (storage buffer). The gel was stored as a 25% suspension (14 mL) in the storage buffer
5 at 4°C. Assuming 100% of the monoclonal antibody bound to the gel, 200 µL of gel suspension contains 143 µg of the monoclonal antibody.

EXAMPLE 5

10 COVALENT ATTACHMENT OF MONOCLONAL ANTIBODY TO HYDRAZIDE GEL

Six milliliters of hydrazide gel (Pierce Chemicals, Carbolink hydrazide, 50% suspension) were washed with 50 mL
15 of 0.1 M phosphate buffer (pH 7.0) in a coarse-porosity sintered-glass funnel. After a gentle vacuum to remove the buffer, the moist gel was transferred to a glass tube with a screw-capped stopper. Five milligrams of monoclonal antibody (concentration, 2 mg/mL), which was dialyzed
20 against 0.1 M phosphate buffer (pH 7.0) at 4°C, was oxidized with 10.5 mg sodium m-periodate at room temperature for 1/2 hour. The oxidized antibody (volume 2.5 mL) was then loaded on a Sephadex G-25 M PD-10 column (Pharmacia) which was pre-equilibrated with 0.1 M phosphate buffer (pH 7.0).
25 The oxidized antibody was eluted with 3 mL of 0.1 M phosphate buffer (pH 7.0) and mixed with the hydrazide gel end-over-end using an infiltration wheel at room temperature for seven hours. The supernatant was checked for the unbound antibody. The amount of antibody bound to the gel ranged between 80-
30 85%. The antibody-immobilized gel was filtered through a coarse-porosity sintered-glass funnel, washed with about 100 mL of 1 M sodium chloride and finally, with 0.05 M TRIS-HCl (pH 7.4) containing 0.15 M sodium chloride and 0.01 % sodium azide (storage buffer). The immobilized gel was stored as a
35 25% suspension in the storage buffer (12 mL) at 4°C. Assuming 80% of antibody bound to gel 400 µL suspension contains about 133 µg of antibody.

EXAMPLE 6COVALENT ATTACHMENT OF MONOCLONAL ANTIBODY TO SULFO
GEL

5

Six milliliters of sulfolink gel (Pierce Chemicals, 50% suspension) were washed in a coarse-porosity sintered-glass funnel with 50 mL of 0.05 M TRIS buffer (pH 8.5) containing 0.005 M EDTA (reaction buffer). After a gentle vacuum to remove the buffer, the moist cake was transferred to a glass tube with a screw-capped stopper. Five milligrams of monoclonal antibody (2 mg/mL), which was dialyzed against 0.1 M phosphate buffer (pH 6) containing 0.005 M EDTA at 4°C, was reduced with 12 mg of 2-mercaptopropylamine HCl (Pierce Chemicals) at 37°C for 1 1/2 hours. The reaction mixture was cooled to room temperature and loaded onto a Sephadex G-25M PD-10 column (Pharmacia) which was pre-equilibrated with the reaction buffer. The reduced antibody was then eluted with 3 mL of the reaction buffer and mixed with the sulfolink gel end-over-end using an infiltration wheel at room temperature for 15 minutes. The reaction mixture was allowed to stand at room temperature for an additional hour. The supernatant was checked for the unbound antibody. The amount of antibody bound to the gel ranged between 75-80%. The gel was filtered through a coarse-porosity sintered-glass funnel, washed with 50 mL of the reaction buffer and again transferred to a glass tube. Three milliliters of 0.05 M cysteine in reaction buffer was added to the gel and mixed end-over-end at room temperature for one hour. The gel was transferred to a coarse-porosity sintered-glass funnel and washed with 50 mL of 1 M sodium chloride and finally, with 50 mL of PBS (pH 7) containing 0.02% sodium azide, (storage buffer). The immobilized gel was stored as a 25% suspension in the storage buffer at 4°C (12 mL). Assuming 75% of antibody bound to the gel, 400 µL of the gel suspension contains 125 µg of antibody.

EXAMPLE 7

PREPARATION OF THE CHOLESTEROL ASSAY REAGENTS

a. Dry Reagents: Methods and formulation are described here to produce sensitive, rapid and stable assay reagents for the quantitation of cholesterol in a fluid phase. Two separate reagents were prepared and were mixed together at the time of the assay. The first reagent formula was comprised of 1.62 g of 3,5-dichloro-2-hydroxybenzenesulfonic acid sodium salt (Aldrich, Milwaukee, Wisconsin) (DCHBS) and 0.428 g of horseradish peroxidase (Amano International, specific activity 82.3 EZ/mg) (HRPO) dissolved in 20.4 mL 0.05 M of 3-(N-Morpholino)-2-hydroxypropanesulfonic acid sodium salt (Sigma) (MOPSO) at pH 7. The solution was then added to 15.8 g of custom made LC06 ww 5.3 frits (Porex Industries; each frit weighed 7.9 mg, volume 8.4 µL) in a brown bottle and mixed end-over-end for 15 minutes. The entire container was then lyophilized to complete dryness. The final moisture content of each frit must be ≤1% as determined by Karl Fisher autotitrator. The first reagent frits were stored dry in a brown bottle at room temperature with some added molecular sieve pouches as a desiccant (Multiform Desiccants). Each frit weighed 8.86 mg on average and contained 0.672 g DCHBS, 0.1786 g HRPO, and 0.1051 g MOPSO. The peroxidase activity of each frit was 14.7 EZ. The second reagent formula was comprised of 0.0113 g MgCl₂.6H₂O, 0.0276 g anhydrous CaCl₂, 0.51 g lactose, 0.51 g dextran (Pharmachem, Mol. Wt. 17,900), 1.02 g bovine serum albumin (Sigma, fatty acid free), 0.30 g glycerol, 0.187 g 4-aminoantipyrine (Aldrich) (AAP), 0.1486 g cholesterol ester hydrolase (Amano International, specific activity 8.4 EZ/mg) (CEH), 0.086 g cholesterol oxidase (Boehringer-Mannheim, specific activity 6.2 EZ/mg) dissolved in 10.2 mL of 0.25 M MOPSO buffer (pH 7). The solution was then added to 9 g of custom made LC06 frits (Porex Industries; each frit weighed 9 mg, volume 8.5 µL) in a brown bottle and then processed as described for the first reagent frits above. The moisture content and storage conditions were also the

- same. Each of the second reagent frits weighed 11.86 mg and were comprised of BSA (0.85 g), dextran (0.425 g), lactose (0.425 g), glycerol (0.255 g), CaCl₂ (0.023 g), MgCl₂ (0.0094 g), AAP (0.156 g), CEH (0.124 g), CO (0.072 g) and MOPSO (0.525 g). The enzyme activities of the second reagent frits were: CEH, 1.04 EZ; CO, 0.445 EZ. Both reagent frits have been found to be stable at room temperature for at least 16 months in terms of their assay performances, in terms of correlation and slope with known cholesterol standards.
- 10 b. Reaction Buffer: The reaction buffer (ICMT) which is also the extraction buffer contained the following materials: 0.05 M MOPSO (pH 7) (Sigma), 1% IgEPal CO-530 (GAF), 0.2% Triton® X-100 (Bio-Rad) and 0.3% cholic acid (Sigma). The
- 15 buffer was sterile filtered and was stored at room temperature. The buffer is stable for at least six months.

EXAMPLE 8

PROTOCOL FOR PREPARATION OF A STANDARD CURVE FOR 20 EVALUATION OF THE IMMUNOCAPTURE ASSAY

Fifty or one hundred microliters of the monoclonal antibody-immobilized gels from Examples 4-6 were transferred to Eppendorf micro centrifuge tube. The tube completely filled.

25 with 5% BSA in PBS and mixed on a TOMY micro tube mixer (Peninsula Laboratories) at room temperature for one hour in order to block the non-specific binding sites of the plastic tube. The tube then centrifuged on a table-top centrifuge for about one minute and the supernatant carefully aspirated. One

30 hundred microliters of purified lipoprotein fractions diluted in PBS were added to the gels. The gel suspensions were mixed on a TOMY mixer at room temperature for one hour. The gels were then washed twice with about 1 mL of PBS by mixing for one minute, centrifuging for one minute and

35 aspirating the supernatants. ICMT solutions (Example 7(b)) were added to each tube to a final volume of 750 µL. Cholesterol assay reagent frits (one each of #1 and #2 from

- Example 7(a)) were added to each tube. The suspensions were mixed on a TOMY mixer for about eight minutes, centrifuged for one minute and the absorbances of the supernatant solutions were read on a DU7400 Spectrophotometer at 515 nm. The concentrations of the gel-bound cholesterol were determined from a cholesterol standard curve. The standard curve was prepared with purified LDL samples having concentrations of 0, 3, 6, 12, 24 and 48 mg/dL following the assay protocol described above (shown in Figure 9).
- 10 EXAMPLE 9
- 15 PROTOCOL FOR LDL-CHOLESTEROL IMMUNOCAPTURE ASSAY
- Four hundred microliters of the monoclonal antibody-immobilized Sepharose 4B gels from Example 4 (about 285 µg of antibody) were transferred to Eppendorf tubes which were previously treated by filling the tubes with 5% BSA in PBS to block all non-specific binding sites. One hundred microliters of individual plasma samples (containing acid-citrate-dextrose or EDTA anticoagulant) were diluted ten-fold in PBS and added to the gels. The gel suspensions were mixed on a TOMY mixer at room temperature for one hour. The gels were then washed twice with about 1 mL of PBS by mixing for one minute, centrifuging for one minute and aspirating the supernatants. ICMT solutions (Example 7(b)) were added to each tube to a final volume of 750 µL. Cholesterol assay reagent frits (one each of #1 and #2 from Example 7(a)) were added to each tube. The suspensions were mixed on a TOMY mixer for about eight minutes, centrifuged for one minute and the absorbances of the supernatant solutions were read on a DU7400 Spectrophotometer at 515 nm. The concentrations of LDL-cholesterol in the plasma samples were determined by multiplying the concentration obtained from the standard curve shown in Figure 9 by 10. The results are shown in Tables 8 and 9, and Figures 10-13 and 16-17.

EXAMPLE 10QUANTITATION OF LDL- AND VLDL-CHOLESTEROL BY
ULTRACENTRIFUGATION-POLYANION PRECIPITATION

5 Plasma samples (7 mL each) were transferred to ultraclear tubes (Beckman, 14 x 95 mm) and then overlaid with 6 mL of d 1.006 g/mL KBr Solution. The samples were centrifuged on a SW40Ti rotor at 40,000 rpm at 4°C for 20 hours. The upper VLDL layers were recovered by a tube-slicing
10 technique. LDL and HDL were recovered in the bottom fraction of each tube. Adequate recovery was verified by comparing the sum of cholesterol in each of the fractions to the total cholesterol of the sample. The cholesterol concentrations of the upper VLDL and lower d >1.006 g/mL (intranet cholesterol)
15 were determined with VISION cholesterol assays (Abbott Laboratories, Abbott Park, Illinois). Assays for HDL-cholesterol concentrations were performed with unfractionated plasma samples using VISION HDL-cholesterol assay (Abbott Laboratories). LDL-cholesterol concentrations were
20 calculated as the difference between total plasma cholesterol and HDL-cholesterol. VLDL-cholesterol concentrations were calculated as the difference between total plasma cholesterol and intranet cholesterol. The results are shown in Table 7.

25 EXAMPLE 11QUANTITATION OF LDL-CHOLESTEROL BY FRIEDEWALD
CALCULATION

30 LDL-cholesterol concentrations were calculated by using the Friedewald equation: [LDL-cholesterol] = [Total-cholesterol] - [HDL-cholesterol] - [Triglycerides/5]. Total cholesterol, HDL-cholesterol and triglycerides were determined with VISION cholesterol assays and VISION triglyceride assay (Abbott Laboratories). The VISION
35 instrument and each lot of reagent cartridges were calibrated prior to running the plasma specimens. The results are shown in Tables 7 and 9.

EXAMPLE 12

PROTOCOL FOR LDL-CHOLESTEROL ASSAY WITH DRY ANTIBODY-GELS

- 5 In order to minimize the time of the assay and also to eliminate the mixing of the test sample with wet gels, the monoclonal antibody 4B5-immobilized Sepharose 4B gel, prepared as described in example 4 of this invention, was used in a dry format. The following is a typical example that was
- 10 used to demonstrate the proof of principle. To an Eppendorf tube, 400 uL of 4B5-Sepharose 4B gel suspension which contained 100 uL of gel and 280 ug antibody was added and then blocked with 1 mL of 5% alkali-treated casein in PBS at room temperature for one hour. The supernatant was aspirated
- 15 off and the wet gel was lyophilized at 25 micron vacuum overnight. To the dried powder gel, 100 uL of a ten-fold diluted plasma in PBS was added. The mixture was incubated at room temperature for 10 minutes without any mixing. One mL of PBS was then added to gel to remove the unbound
- 20 material. After a brief centrifugation and aspiration of the supernatant, the gel was rewashed once again. ICMT solution was then added to the gel to a final volume of 750 uL. After addition of the cholesterol assay reagents, the absorbance of the supernatant solution was read on DU7400
- 25 Spectrophotometer at 515 nm. The concentration of the gel-bound cholesterol was obtained from a cholesterol standard curve similar to that shown in Figure 9. The correlation between LDL-cholesterol assays as calculated by the Friedewald equation and by this protocol is illustrated in
- 30 Figure 20.

EXAMPLE 13

PROTOCOL FOR AN INDIRECT LDL-CHOLESTEROL ASSAY WITH ANTIBODY GEL

35

This protocol was developed for the following reasons:

- 1) to demonstrate that 4B5-Sepharose 4B gel specifically and

completely captured the LDL particles from plasma samples used in the direct immunocapture assay; 2) to develop an indirect LDL-cholesterol assay which could be useful in commercial instruments, such as Abbott Vision. The assay 5 format involves the specific capture of LDL particles on 4B5-Sepharose 4B gel and then assay the unbound supernatant containing lipoproteins other than LDL, namely VLDL, IDL, HDL and Lp(a). LDL-cholesterol is then calculated by subtracting from the total cholesterol:

10

$$[\text{LDL-chol}] = [\text{Total-chol}] - [\text{Supernatant-chol}].$$

The following is a typical protocol used in the present invention. To an Eppendorf tube, 400 uL of 4B5-Sepharose 15 which contained 100 uL of gel and 280 ug antibody was added and then blocked with 1 mL of 5% alkali-treated casein in PBS at room temperature for one hour. The supernatant was aspirated off. One hundred microliters of a ten-fold diluted plasma in PBS was added. After mixing at room temperature 20 for ten minutes, 150 uL of PBS was added to the mixture. After a brief centrifugation, ICMT solution was added to the supernatant to a final volume of 750 uL. The cholesterol content in the supernatant was determined as described in example 10. The correlation between LDL-cholesterol assays 25 as calculated by the Friedewald equation and by this indirect method is illustrated in Figure 21. It should be noted that similar results were also obtained using dry 4B5-Sepharose 4B gel.

30 Lp(a)-CHOLESTEROL SPECIFIC ASSAY

The present invention is further directed to a method for the direct measurement of Lp(a)-cholesterol in plasma, preferably using sandwich immunoassay methodology. A 35 specific binding agent, preferably an antibody and more preferably a monoclonal antibody, specific for Lp(a) is used to capture Lp(a) particles in a plasma sample. The cholesterol

associated with the Lp(a) particles is then measured as described earlier herein. Preferably, the captured Lp(a) particles are separated from the remainder of the sample prior to the cholesterol measurement. To simplify the
5 separation process, the Lp(a) specific binding agent is preferably coupled to a solid phase as described earlier herein.

EXAMPLE 14

PREPARATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR LP(A)

10

Female BALB/c mice were immunized four times in 2-3 week intervals with 50 µg of apo(a) protein which was emulsified with Ribi adjuvant (Ribi Immunochem Research, Inc., Hamilton, MT). Four days after the last boosting, the mice
15 were sacrificed and the immune spleen cells were fused with myeloma cells SP2/0 according to the procedure reported by Gefter, et al. (1977) Somatic Cell Genet. 3:231. After two to three weeks of hybrid cell growth in microtiter plate wells, tissue culture spent media were collected from hybrid
20 growing wells and tested for Lp(a) binding monoclonal antibodies. The screening procedure was carried out by first incubating the tissue culture spent media on a Lp(a) or Apo(a) coated microtiter plate. Then, after removing the media and washing the wells, horseradish peroxidase labeled goat anti-mouse antibody was incubated in the wells. The wells were
25 again washed and o-phenylenediamine was added to each well for signal development. The microtiter plate was read at 492 nm using a microtiter plate reader. The presence and/or amount of signal development indicated the presence and/or
30 concentration of anti-Lp(a) antibody produced in the tissue culture spent media.

The Lp(a) specific monoclonal antibodies 4D2, 1E1 and 4F2 prepared by the above method were purified on a Protein A-Sepharose 4B column (commercially available from
35 Pharmacia) using 100 mM citrate buffer, pH 6.0, to elute the antibodies from the column. The antibodies did not show any cross-reactivity with LDL, VLDL, IDL and HDL. Also, these

antibodies did not show any significant inhibition of binding to Lp(a) coated microtiter plates with human plasminogen up to 1 mg/mL.

5 **EXAMPLE 15**

PREPARATION OF Lp(a) STANDARDS AND CALIBRATORS

- Lp(a) concentrations in fresh plasma samples were measured using a commercial ELISA test for Lp(a) (TERUMO Medical Corp., Elkton, MD). Plasma samples with high Lp(a) concentrations were ultracentrifuged for 20 hours at 40,000 rpm at a density of 1.080 g/mL. The upper lipoprotein fraction containing Lp(a), LDL, VLDL and IDL was dialyzed and then the Lp(a) was affinity purified on a Lp(a) specific monoclonal antibody (4F2) Sepharose 4B column using standard procedures well known in the art. The purity of the Lp(a) obtained from the column was determined by polyacrylamide gel electrophoresis under denatured conditions, by SDS-PAGE electrophoresis under reducing conditions and by Western Blot.
- The protein content of the Lp(a) obtained form the column was measured by Lowry assay and the cholesterol concentration was measured using the Abbott Vision® Cholesterol Assay (commercially available from Abbott Laboratories, Abbott Park, IL). Lp(a) standards having a protein concentration within the range of about 0.3 mg/mL and about 0.6 mg/mL were prepared from the purified Lp(a) by dilution in 20 mM phosphate buffered saline at pH 7.4 or 1% alkali-treated casein in 20 mM phosphate buffered saline at pH 7.4. Calibrators having Lp(a)-cholesterol concentrations of 0, 2.4, 4.85, 9.7, 19.5, 38.9, 77.8, 155.6 and 311 µg/mL were prepared by dilution of the Lp(a) standards in 20 mM phosphate buffered saline at pH 7.4 or 1% alkali-treated casein in 20 mM phosphate buffered saline at pH 7.4. The Lp(a) standards and calibrators were stored at 4°C.

EXAMPLE 16

PREPARATION OF DIGITONIN-PEROXIDASE CONJUGATE

Three parts of a digitonin solution (2.5 mg/mL in water) 5 (Sigma Chemical company, St. Louis, MO) was mixed with one part of a fresh solution of sodium meta-periodate (1.68% w/v in water) at 4°C for one hour and then the mixture was dialyzed against 20 mM phosphate buffered saline (PBS), pH 8.0 at 4°C overnight. One part of a solution of 0.25 M 10 ethylenediamine in 20 mM PBS, pH 8.0, was added to four parts of the dialyzed mixture and the mixture was incubated at 4°C. After 30 minutes and again after 60 minutes of incubation, 100 µL of a sodium borohydride solution (4 mg/mL in 0.1N NaOH) was added to the mixture for each 30 mg of 15 digitonin in the mixture. The mixture was then incubated for two hours at 4°C. The resulting mixture containing ethylenediamine derivatized digitonin was dialyzed against 0.01 M carbonate buffer, pH 9.5, at 4°C overnight. The final carbonate buffer solution of ethylenediamine derivatized 20 digitonin contained about 1.5 mg digitonin/mL buffer.

Twenty-five milligrams of horseradish peroxidase (HRPO) (155 Ku/mg, commercially available from Amano International) were dissolved in 6.25 mL of water and 1.25 mL of freshly prepared 0.2 M sodium meta-periodate was added. 25 After 20 minutes in the dark at room temperature, the reaction was dialyzed against 4 liters of 1 mM acetate buffer, pH 4.5, at 4°C for 4 hours. The oxidized HRPO solution and the ethylenediamine derivatized digitonin solution were mixed and stirred in the dark at room temperature for two hours. Then 30 400 µL of a sodium borohydride solution (4 mg/mL in water) was added and the reaction was incubated at 4°C. After two hours, the mixture was dialyzed against 20 mM PBS, pH 7.4, at 4°C overnight. One part of 5% w/v aqueous sodium deoxycholate was added to 10 parts of the dialyzed reaction 35 mixture and fatty acid free bovine serum albumin (BSA) (Sigma Chemical Company) was added to a final concentration of 5 mg/mL. The solution of HRPO-digitonin conjugate was

sterile filtered through a 0.22 micro filter (Coaster Labs) and stored at -20°C.

The binding curves of the HRPO-digitonin conjugate binding to Lp(a)-cholesterol, LDL-cholesterol and VLDL-cholesterol particles were obtained (see Figure 22). Maxisob Nunc Immuno plates were coated by incubating in separate wells 100 µL of a solution containing pure Lp(a), LDL or VLDL having a cholesterol concentration of about 5 µg/mL in 20 mM PBS, at pH 7.4, at 37°C for one hour. The wells were washed five times with 0.05% w/v Tween 20 in 20 mM PBS, at pH 7.4 (PBS-Tween) and then blocked with 200 µL of 5% w/v BSA in 20 mM PBS, at pH 7.4, by incubation at 37°C for one hour. The HRPO-digitonin conjugate solution was serially diluted in the wells with a solution of 5 µg/mL of alkali-treated casein in 20 mM PBS, at pH 7.4 (100µL total volume in each well). After incubation at 37°C for one hour, the wells were washed eight times with PBS-Tween. One hundred microliters of a o-phenylenediamine substrate solution (commercially available from Abbott Laboratories) was added to each well and after five minutes, the reaction was quenched with the addition of 100 µL of 1N sulfuric acid. The absorbance in each well was measured on a Bio-Tek microplate reader at 490 nm.

EXAMPLE 17

25 Lp(a)-CHOLESTEROL ASSAY

The monoclonal antibody 1E1 was diluted in 20 mM PBS, at pH 7.4, to a concentration of 5 µg/mL. One hundred microliters of the 1E1 solution was added to the wells of Maxisob Nunc Immuno plates and the plates were incubated at room temperature on a rotator at 100 rpm for two hours. The plates were washed five times with PBS-Tween solutions and then blocked with 200 µL of 5% w/v BSA in 20 mM PBS, at pH 7.4, by incubation at 37°C for one hour. The plates can be stored at 4°C with plastic sealers at least for ten days prior to use.

Plasma samples were diluted 201-fold with 1% w/v alkali-treated casein in 20 mM PBS, at pH 7.4. One hundred microliters of the diluted samples were added to each well of the 1E1 plates and the plates were incubated at 37°C for one hour. After washing the plates five times with PBS-Tween, 100 µL of HRPO-digitonin conjugate (2 µg/mL in 1% w/v alkali-treated casein in 20 mM PBS at pH 7.4) were added to each well. The plates were incubated at 37°C for one hour and then washed ten times with PBS-Tween. One-hundred microliters of a freshly prepared solution of o-phenylenediamine in citrate buffer (substrate commercially available from Abbott Laboratories) were added to each well and after five minutes, the reaction was quenched with 100 µL of 1N sulfuric acid. The absorbance of each well was measured on a Bio-Tek microplate reader at 490 nm. The Lp(a)-cholesterol concentration was then determined from a standard curve of absorbance versus Lp(a)-cholesterol concentration.

20 EXAMPLE 18

Lp(a)-CHOLESTEROL CALIBRATION CURVE

Lp(a)-cholesterol standards were prepared from Lp(a) standard solutions as described in Example 15. Calibrators having Lp(a)-cholesterol concentrations of 0, 2.4, 4.85, 9.7, 19.5, 38.9, 77.8, 155.6 and 311 µg/mL were assayed by the method described in Example 17. The concentrations were multiplied by 201 to generate the standard curve because the plasma samples were diluted 201-fold prior to performing the assay. A plot of Lp(a)-cholesterol concentration versus absorbance was prepared from the resulting data. Figure 23 is illustrative of such a plot. The Lp(a)-cholesterol concentration in unknown samples can be determined from the calibration curve. Generally the calibrators and the plasma samples were assayed on the same plate to minimize the effect of variations in the reagents, materials and conditions.

The number and concentration of calibrators can be readily altered depending on the desired accuracy of the results.

EXAMPLE 19

5. PLASMA SAMPLES

The lipid profiles of 64 plasma samples from individuals without known cardiac problems ("N") and patients with mixed hyperlipidemia ("MHL"), hypocholesterolemia ("HC") and mild 10 hypocholesterolemia ("MHC") were determined by the methods described earlier herein and the results are shown in Table 11. Total cholesterol, HDL-cholesterol and triglyceride concentrations were measured using an Abbott Vision® instrument and reagents (commercially available from Abbott 15 Laboratories, Abbott Park, IL).

The Lp(a)-cholesterol concentrations of the samples were determined using a commercial ELISA test for Lp(a) (TERUMO Medical Corp., Elkton, MD), standard calculated values based on the total Lp(a) concentration and the method of the 20 present invention disclosed in Example 17. The results are summarized in Table 12. The results in Table 12 illustrate the good correlation between the TERUMO ELISA method and the method of the present method (correlation coefficient (r) = 0.983; slope - 0.935; and intercept = 0.712) for normal 25 individuals. The TERUMO ELISA method tended to produce erroneous results for the cardiac patient samples, especially those with high concentrations of Lp(a) (>40 mg/dL). The results obtained by the present method had excellent correlation with the Lp(a)-protein assay method for samples 30 from both normal individuals and cardiac patients (correlation coefficient (r) = 0.972; slope = 0.997; intercept = 1.0).

The data in Table 12 appears to indicate that the cholesterol content in Lp(a) particles is not constant for each individual and hence the assumptions behind the calculated 35 values of Lp(a)-cholesterol are erroneous. With the discovery of the present invention, it is now possible to accurately measure the Lp(a)-cholesterol plasma concentration directly

rather than assume that a constant relationship exists for all individuals. The correlation between disease states and Lp(a)-cholesterol concentrations can now be readily established using the present invention. In addition, the
 5 effect of proposed treatments of such disease states can now be easily monitored using the present invention.

TABLE 11
LIPID PROFILES OF Lp(a) PLASMA SAMPLES

Sampl. No.	Total Chol. mg/dL	HDL- Chol. mg/dL	TRIG ¹ mg/dL	F.E. ² LDL- Chol. mg/dL	U.C. ³ LDL- Chol. mg/dL	U.C. ⁴ VLDL- Chol. mg/dL	Sampl. Type
101	253	50	80	187	179	23	N
102	175	70	50	95	92	13	N
103	245	50	140	167	148	47	N
104	167	53	120	90	90	24	N
105	239	76	60	151	142	21	N
106	198	34	110	141	131	33	N
107	177	43	200	94	97	37	N
108	171	32	135	112	104	35	N
109	213	58	75	141	143	12	N
110	224	50	290	108	108	67	N
111	200	50	125	124	111	39	N
112	194	68	75	111	106	20	N
113	181	55	50	117	114	12	N
114	194	62	60	121	126	12	N
115	240	52	105	167	165	23	N
116	155	57	60	85	84	12*	N
117	179	43	72	122	118	14*	N
118	152	68	35	77	74	10	N
119	193	34	175	123	119	40	N
120	251	41	144	182	185	29*	N
121	168	43	106	104	110	21*	N
122	283	42	530		171	71	N
123	172	55	67	104	101	13*	N
124	203	50	118	130	132	24*	N

125	183	43	111	118	120	22*	N
126	134	56	55	67	66	12	N
127	156	50	54	96	92	11*	N
128	289	50	240	191	176	63	N
129	143	50	49	83	85	10*	N
130	160	61	52	89	87	10*	N
131	201	41	82	144	138	16*	N
132	180	30	198	110	115	40*	N
133	186	53	83	116	116	17*	N
134	220	52	93	149	145	19*	N
135	227	35	243	144	140	49*	N
136	167	55	45	102	98	9*	N
137	239	35	489		125	79	MHL
138	217	48	181	133	145	24	MHL
139	250	26	289	166	160	64	MHL
140	183	32	292	93	109	42	N
141	140	25	226	70	90	17	HC
142	257	50	84	190	163	14	HC
143	199	60	121	115	115	24*	N
144	222	51	73	156	156	15*	MHC
145	226	48	127	153	153	25*	MHC
146	192	32	168	126	126	34*	N
147	215	36	79	163	163	16*	MHC
148	267	35	138	204	204	28*	HC
149	225	20	464				MHL
150	186	29	531		87	70	N
151	245	50	136	168	173	22	HC
152	249	68	79	165	169	12	HC
153	236	37	256	148	138	61	MHL
154	160	26	111	112	109	13	N
155	141	49	131	66	81	11	HC
156	197	35	214	119	137	25	N
157	236	38	381	122	136	62	MHL
158	235	77	190	120	120	38*	MHL
159	153	48	123	80	80	25*	N
160	154	45	118	85	85	24*	N
161	169	64	61	93	93	12*	N

76

162	180	47	132	107	120	13	N
163	177	40	61	125	127	10	N
164	200	58	87	125	136	6	N

¹ TRIG = triglyceride concentration.² F.E. = Friedewald Equation:

$$[\text{LDL-Chol}] = [\text{Total Chol}] - [\text{HDL-Chol}] - [\text{TRIG}/5].$$

³ U.C. = Ultracentrifuge β-quantitation:

$$[\text{LDL-Chol}] = [d > 1.006 \text{ Infranate-Chol}] - [\text{HDL-Chol}].$$

⁴ U.C. = Ultracentrifuge β-quantitation:

$$[\text{VLDL-Chol}] = [\text{Total Chol}] - [d > 1.006 \text{ Infranate-Chol}].$$

* Calculated by dividing the triglyceride concentration by 5.

10

TABLE 12
Lp(a)-CHOLESTEROL LEVELS OF PLASMA SAMPLES

Sampl. No.	TERUMO ¹ Lp(a) mg/dL	TERUMO ² Lp(a)- Chol. mg/dL	EIA ³ Lp(a)- Chol. mg/dL	ELISA ⁴ Lp(a) mg/dL	ELISA ² Lp(a)- Chol. mg/dL	Sampl. Type
101	19.6	5.88	5.6			N
102	7.9	2.1	3.8			N
103	80.6	24.2	24.5			N
104	15.14	4.54	5.2			N
105	35.88	10.76	8.8			N
106	2.68	0.8	0.66			N
107	1.16	0.3	0.2			N
108	10.2	3.1	4.4			N
109	12.72	3.8	2.96			N
110	18.36	5.5	5.67			N
111	7.5	2.3	3.2			N
112	14.64	4.4	4.1			N
113	84.2	25.2	21.5			N
114	65.3	19.6	21.5			N
115	25.69	7.7	5.6			N
116	12.5	3.74	4.69			N
117	4.86	1.46	3.76			N
118	4.23	1.27	1.38			

119	9.2	2.8	4.8			N
120	65.3	19.6	17.7			N
121	14.7	4.4	4.4			N
122	0.7	0.2	0.12			N
123	35.7	10.7	12.5			N
124	0.78	0.2	0.1			N
125	62.6	18.8	19.88			N
126	4.6	1.4	2.1			N
127	1.8	0.5	0.34			N
128	3.2	0.97	0.6			N
129	6.7	2.0	2.9			N
130	3.3	1.0	2.5			N
131	13.3	4.0	5.9			N
132	10.0	3.0	4.6			N
133	6.7	2.0	3.1			N
134	0.7	0.2	0.13			N
135	1.34	0.4	0.57			N
136	6.7	2.0	3.7			N
137	1.6	0.48	0.66	2.48	0.74	MHL
138	10.53	3.2	5.23	7.58	2.3	MHL
139	36.2	10.86	5.2	18.95	5.68	MHL
140	3.16	0.95	0.45	2.65	0.8	N
141*	65.68	19.7	19.7	61.5	18.4	HC
142*	67.36	20.2	33.6	94.3	28.3	HC
143*	88.4	26.5	22.4	82.94	24.88	N
144*	46.73	14.02	13.8	35.36	10.61	MHC
145	17.68	5.3	7.59	11.37	3.41	MHC
146	12.2	3.66	3.32	5.47	1.64	N
147*	60.6	18.19	17.56	39.57	11.87	MHC
148	22.73	6.82	8.46	13.47	4.0	HC
149	28.63	8.59	4.5	15.58	4.7	MHL
150	7.36	2.21	0.84	5.47	1.64	N
151*	78.3	23.49	14.7	48.84	14.65	HC
152*	78.3	23.49	13.74	47.99	14.4	HC
153	18.5	5.5	4.05	11.79	3.54	MHL
154	55.57	16.67	9.97	36.2	10.86	N
155	0.0	0.0	0.16	0.37	0.11	HC

156	11.58	3.47	3.4	5.05	1.52	N
157	2.53	0.76	0.86	1.98	0.59	MHL
158	12.63	3.79	3.67	8.84	2.65	MHL
159*	72.0	21.6	22.26	81.25	24.38	N
160*	67.8	20.33	20.78	66.1	19.8	N
161	1.05	0.32	0.21	0.93	0.28	N
162	20.0	6.0	3.4	6.74	2.0	N
163	20.63	6.19	3.75	10.94	3.28	N
164	5.26	1.59	3.1	8.4	2.5	N

1 Total Lp(a) measured by TERUMO ELISA test.

2 Lp(a)-Cholesterol calculated from Total Lp(a) by multiplying Total Lp(a) by 0.3.

3 Lp(a)-Cholesterol measured directly by EIA according to Example 16.

4 Total Lp(a) calculated by multiplying the Lp(a)-protein concentration [measured by an ELISA method at the University of Chicago (Dr. A. Scamn)] by 4.21.

* Samples diluted two-fold prior to assay.

10

SEQUENCE LISTING

(1) GENERAL INFORMATION:

15

(i) APPLICANT: ABBOTT LABORATORIES

20

(ii) TITLE OF INVENTION: IMMUNOCAPTURE ASSAY FOR DIRECT QUANTIUTATION OF SPECIFIC LIPOPROTEIN CHOLESTEROL LEVELS

(iii) NUMBER OF SEQUENCES: 2

25

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: ABBOTT LABORATORIES D-377 AP-6D

(B) STREET: ONE ABBOTT PARK ROAD

(C) CITY: ABBOTT PARK

- (D) STATE: ILLINOIS
- (E) COUNTRY: UNITED STATES OF AMERICA
- (F) ZIP: 60064-3500

5 (v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE:

10

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 07/968,619
- (B) FILING DATE: 29-OCT-1992

15

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 07/847,502
- (B) FILING DATE: 06-MAR-1992

20

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: UNGEMACH, FRANK S
- (B) REGISTRATRION NUMBER: 34449
- (C) REFERENCE/DOCKET NUMBER: 5144.PC.O1

25

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 708-937-8360
- (B) TELEFAX: 708-938-2623

(2) INFORMATION FOR SEQ ID NO:1:

30

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	Glu	Phe	His	Met	Lys	Val	Lys	His	Leu	Ile	Asp	Ser	Leu
	1				5						10		
5	Ile	Asp	Phe	Leu	Asn	Phe	Pro	Arg	Phe	Gln	Phe	Pro	Gly
		15					20					25	
	Lys	Pro	Gly	Ile	Tyr	Thr	Arg	Glu	Glu	Leu			
				30					35				

10 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

	Ser	Met	Pro	Ser	Phe	Ser	Ile	Leu	Gly	Ser	Asp	Val	Arg
	1				5					10			
25	Val	Pro	Ser	Tyr	Thr	Leu	Ile	Leu	Pro	Ser	Leu	Glu	Leu
			15				20					25	
	Pro	Val	Leu	His	Val	Pro	Arg	Asn	Lys				
					30				35				

30 The embodiments described and the alternative
embodiments presented are intended as examples rather than
as limitations. Thus, the description of the invention is not
intended to limit the invention to the particular embodiments
disclosed, but it is intended to encompass all equivalents and
35 subject matter within the spirit and scope of the invention as
described above and as set forth in the following claims.

WHAT IS CLAIMED IS:

1. A method for determining the amount of cholesterol associated with a specific lipoprotein in a sample comprising:
 - a. mixing a sample and a lipoprotein specific binding agent such that binding-agent-lipoprotein complexes are formed; and
 - b. determining the amount of cholesterol bound to said binding-agent-lipoprotein complexes.
2. The method of claim 1 wherein said lipoprotein specific binding agent is coupled to a solid support.
3. The method of claim 2 further comprising the step of separating the solid support from the sample before determining the amount of cholesterol bound to said binding-agent-lipoprotein complexes.
4. The method of claim 3 wherein said determination comprises releasing said cholesterol bound to said binding-agent-lipoprotein complexes and measuring the amount of cholesterol released.
5. The method of claim 3 wherein said determination comprises mixing said binding-agent-lipoprotein complexes with a cholesterol specific binding agent coupled to a detectable label such that a second complex is formed and determining the amount of label bound to said second complex.
6. The method of claim 2 wherein the solid support is selected from the group consisting of nitrocellulose, latex, nylon and polystyrene.
7. The method of claim 1 wherein the solid support is selected from the group consisting of beads, particles, magnetic particles, and glass fiber.
8. The method of claim 1 further comprising the step of separating said binding-agent-lipoprotein complexes from the sample before determining the amount of cholesterol bound to said binding-agent-lipoprotein complexes.
9. The method of claim 8 wherein
 - a. said lipoprotein specific binding agent is conjugated to a first charged substance; and
 - b. said separation comprises:

- i. contacting said binding-agent-lipoprotein complexes with an insoluble solid phase material which is oppositely charged with respect to said first charged substance, such that said solid phase material attracts and attaches to said first charged substance; and
 - ii. separating said solid phase material and said sample.
10. The method of claim 9 wherein said charged substances are anionic and cationic monomers or polymers.
11. The method of claim 8 wherein said determination comprises releasing said cholesterol bound to said binding-agent-lipoprotein complexes and measuring the amount of cholesterol released.
12. The method of claim 8 wherein said determination comprises mixing said binding-agent-lipoprotein complexes with a cholesterol specific binding agent coupled to a detectable label such that a second complex is formed and determining the amount of label bound to said second complex.
13. The method of claim 12 wherein said cholesterol specific binding agent coupled to a detectable label is added and said second complex is formed prior to said separation step.
14. The method of claim 1 wherein said specific lipoprotein is selected from the group consisting of LDL, HDL, VLDL, IDL and Lp(a).
15. The method of claim 1 wherein said lipoprotein specific binding agent is a monoclonal or a polyclonal antibody that specifically binds to a lipoprotein selected from the group consisting of LDL, HDL, VLDL, IDL and Lp(a).
30. 16. A method for determining the amount of LDL-cholesterol in a sample comprising:
 - a. mixing a sample and an LDL specific binding agent coupled to a solid support; and
 - b. determining the amount of LDL-cholesterol bound to said solid support.
35. 17. The method of claim 16 further comprising the step of separating the solid support from the sample before

determining the amount of LDL-cholesterol bound to said solid support.

18. The method of claim 16 wherein the LDL specific binding agent is an antibody that binds to substantially all LDL, to VLDL at less than about 20% of LDL binding, to IDL at less than about 20% of LDL binding, to Lp(a) at less than about 5% of LDL binding, and to HDL at less than about 2% of LDL binding.
19. The method of claim 16 wherein said solid support is selected from the group consisting of nitrocellulose, latex, nylon and polystyrene.
20. A method for determining the amount of LDL in a sample comprising:
 - a. mixing a sample and an LDL specific binding agent coupled to a solid support; and
 - b. determining the amount of LDL bound to said solid support.
21. The method of claim 20 further comprising the step of separating the solid support from the sample before determining the amount of LDL bound to said solid support.
22. The method of claim 20 wherein the LDL specific binding agent is a monoclonal or a polyclonal antibody or fragment thereof that binds to substantially all LDL, to VLDL at less than about 20% of LDL binding, to IDL at less than about 20% of LDL binding, to Lp(a) at less than about 5% of LDL binding, and to HDL at less than about 2% of LDL binding.
23. The method of claim 20 wherein said solid support is selected from the group consisting of nitrocellulose, latex, nylon and polystyrene.
24. An antibody specific for LDL and useful in an LDL specific immunoassay produced by immunization of a mammal with a fragment of LDL containing the T2 region of LDL or subfragment of the T2 region of LDL, where said antibody binds to substantially all LDL, to VLDL at less than about 20% of LDL binding, to IDL at less than about 20% of LDL binding, to Lp(a) at less than about 5% of LDL binding, and to HDL at less than about 2% of LDL binding.

25. A monoclonal antibody specific for LDL prepared by the method comprising the steps of:
- a. immunizing a mouse or a rat with a fragment of LDL containing the T2 region of LDL or subfragment of the T2 region of LDL;
 - b. making a suspension of the mouse or rat spleen cells;
 - c. fusing the spleen cells with mouse or rat myeloma cells in the presence of a fusion promoter;
 - d. culturing the fused cells;
 - 10 e. determining the presence of anti-LDL antibody in the culture media;
 - f. cloning a hybridoma producing antibody that binds to substantially all LDL, to VLDL at less than about 20% of LDL binding, to IDL at less than about 20% of LDL binding, to Lp(a) at less than about 5% of LDL binding, and to HDL at less than about 2% of LDL binding; and
 - 15 g. obtaining the antibody from said hybridoma.
26. A method for determining the amount of Lp(a)-cholesterol in a sample comprising:
- 20 a. mixing a sample and an Lp(a) specific binding agent coupled to a solid support;
 - b. separating the solid support from the sample; and
 - c. determining the amount of cholesterol bound to said solid support.
- 25 27. The method of claim 26 wherein the Lp(a) specific binding agent is a monoclonal or a polyclonal antibody or fragment thereof.

1/24




FIG. 1

2/24




FIG. 2

3/24




FIG. 3

4/24





FIG. 4

5/24



6/24




FIG. 6

7/24




FIG. 7A

8/24




FIG. 7B

9/24

RESIDUE 4154-4189 OF ApoB100 T2 FRAGMENT
(SEQ ID NO 1)

Glu Phe His Met Lys Val Lys His Leu Ile Asp Ser Leu Ile Asp
4155 4160 4165
Phe Leu Asn Phe Pro Arg Phe Gln Phe Pro Gly Lys Pro Gly Ile
4170 4175 4180
Tyr Thr Arg Glu Glu Leu
4185

FIG. 8A

LDL B RECEPTOR RESIDUE 3252-3286
(SEQ ID NO 2)

Ser Met Pro Ser Phe Ser Ile Leu Gly Ser Asp Val Arg Val Pro
3255 3260 3265
Ser Tyr Thr Leu Ile Leu Pro Ser Leu Glu Leu Pro Val Leu His
3270 3275 3280
Val Pro Arg Asn Lys
3285

FIG. 8B

10/24




FIG. 9

11/24




FIG. 10A




FIG. 10B

12/24




FIG. 11A




FIG. 11B

13/24




FIG. 12 A




FIG. 12 B

14/24




FIG. 13A




FIG. 13 B

15/24




FIG. 14A




FIG. 14B

SUBSTITUTED QUET

16/24




FIG. 15A




FIG. 15 D

17/24




FIG. 16A




FIG. 16 B

18/24




FIG. 17A




FIG. 17B

19/24




FIG. 18A




FIG. 18B

20/24




FIG. 19A




FIG. 1QR

21/24




FIG. 20

22/24




FIG. 21

23/24




FIG. 22

24/24




FIG. 23

INTERNATIONAL SEARCH REPORT

International application N .
PCT/US93/02011

A. CLASSIFICATION OF SUBJECT MATTER

IPC(S) :C07K 15/28, 17/02, 17/14; G01N 33/92, 33/537, 33/544, 33/551

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1, 172.2, 240.27; 436/71, 524, 526, 528, 538, 548; 530/388.25, 389.3, 391.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE search terms: lipoprotein, cholesterol, antibody, assay, Lp(a), LDL; SEQUENCE search in A-GENESEQ-8, PIR 33, SWISS-PROT 23

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4,126,416 (SEARS) 21 November 1978, see col. 2, lines 14-21 and 51-56; col. 3, lines 1-11.	<u>1,8,14</u> 2 , 3 , 5 - 7 , 9,10,12,13, 15-19,26,27
X	US, A, 4,698,298 (DEDIEU et al) 06 October 1987, col. 1, lines 47-51; col. 2, line 58 through col. 3, line 32; col. 4, lines 57-68; col. 11, lines 30-68; col. 13, lines 21-54.	<u>20,21,23</u> 22

<input checked="" type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
"*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
17 May 1993	07 JUN 1993
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Facsimile No. <u>N/A</u> APPLICABLE	Authorized officer NANCY PARSONS Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/02011

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	CLINICA CHIMICA ACTA, Volume 191, issued 1990, M. LaBelle et al, "Increased immunoreactivity of apolipoprotein B epitopes during prolonged storage of low density lipoproteins", pages 153-160, especially pages 155,156.	<u>24,25</u> 22
X Y	NATURE, Volume 323, issued 23 October 1986, T.J. Knott et al, "Complete protein sequence and identification of structural domains of human apolipoprotein B", pages 734-738, especially page 737.	<u>24,25</u> 22
Y	US, A, 4,619,895 (CUBICCIOTTI et al) 28 October 1986, col. 4; col. 10, lines 15-34; col. 14, lines 34-68; col. 15, lines 24-31.	2,3,5-7,12, 13, 15-19, 26, 27
Y	US, A, 4,935,147, (ULLMAN et al) 19 June 1990, col. 3, lines 56-64; col. 4, lines 23-35; col. 7, lines 25-28 and 42-44; col. 10, lines 34-46; col. 11, line 65 through col. 12, line 3; col. 13, lines 6-8; col. 17, lines 1-5.	9,10
Y	US, A, 4,885,256 (ALVING et al) 05 December 1989, columns 2 and 8.	5,12,13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/02011

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

435/7.1, 172.2, 240.27; 436/71, 524, 526, 528, 538, 548; 530/388.25, 389.3, 391.1